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ABSTRACT 
Despite improvements in stimulation protocols, culture media formulations and laboratory 
protocols, the success rates in human IVF remain disappointingly low. The ability to 
successfully cryopreserve supernumerary embryos in a given IVF cycle without losing 
significant embryo viability is essential to maximize the cumulative benefit of a given treatment 
cycle. Therefore, studies on culture, cryopreservation and gene expression of human embryos 
fertilized in vitro were performed.                                                                                                                                                                          
 
In these studies the impact of culture media on fertilization of human oocytes in vitro was 
investigated. Furthermore, the impact of growth factor supplementation to in vitro culture media 
and embryo survival and cryodamage after vitrification were studied. Using in situ 
hybridization and immunohistochemistry methods, the expression of genes in the human 
Fallopian tube, endometrium, and pre-implantation embryos and in human embryonic stem 
cells (hES) cells was studied.  
 
The findings can be summarized as follows: in vitro culture media has impact on normal 
fertilization. Supplementation of growth factors to in vitro culture media implicates a 
physiological role in regulating pre-implantation development. Vitrification of embryos is an 
effective way of cryopreservation. In situ hybridization, immunohistochemical and matrix 
assisted laser desorption/ionization time of flight mass spectrometry methods are versatile tools 
in reproductive medicine research.  
 
These findings will help to identify markers for embryo development and characterisation of 
hESC. Furthermore, knowledge obtained will give us tools to improve formulations of culture 
and cryopreservation media, which in turn might increase the overall results in IVF treatment 
and maximise the usage of hESC.  
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1 INTRODUCTION 
 
Infertility, whether male or female, is defined by the World Health Organization 
(WHO) as the inability of a couple to achieve conception or bring a pregnancy to term 
after one year or more of regular, unprotected sexual intercourse. It is estimated that 
around 60 - 80 million couples worldwide experience some sort of infertility. 
According to WHO, between 2 and 10 % of couples worldwide are unable to conceive 
a child and a further 10 – 25 % experience secondary infertility i.e. inability to conceive 
after one or more successful pregnancies (Boivin, Bunting et al. 2007). Infertility is not 
only a medical problem; it is regarded as psychologically stressful by most individuals 
and can lead to social isolation (Johansson and Berg 2005).  
Assisted reproduction technology (ART) is a common name used to describe the set of 
various methods to help infertile couples to have a child. Conventional in vitro 
fertilization (IVF) and intracytoplasmic sperm injection (ICSI) being the two main 
methods used to date.    
Since the birth of the first child after IVF on July 25 1978 (Steptoe and Edwards 1978), 
the number of ART children has increased steadily. In vitro fertilization is now 
acknowledged to be an effective treatment for infertility. At present, more than 2 % of 
all newborns are conceived with the help of IVF. Improved pregnancy and delivery 
rates per aspiration for IVF, ICSI and frozen embryo replacement (FER) have been 
reported.  Recent studies show that pregnancy rates of 29.1 % and 28.6 % per aspiration 
for IVF and ICSI, and 20.1 % per thawing for FER can be achieved. Mean delivery 
rates per aspiration (per thawing for FER) are  21.1, 20.2 and 13.5 %, respectively (de 
Mouzon, Goossens et al. 2012). The development of human IVF was acknowledged by 
awarding Dr. R.G Edwards the 2010 Nobel Prize in Physiology or Medicine.  
Unfortunately there are risks associated with ART, despite the fact that children born 
after IVF in general are as healthy as children conceived after natural conception 
(Ludwig, Sutcliffe et al. 2006; Basatemur and Sutcliffe 2008). Recent observations 
suggest a link between ART and epigenetic errors. Two imprinting disorders, 
Beckwith-Wiedemann Syndrome (BWS) and Angelman Syndrome (AS), have been 
associated with the use of IVF (Amor and Halliday 2008).   
Women undergoing ART face an increased risk of multiple pregnancies due to the 
practice of transferring two or more embryos. The rationale to reduce multiple 
pregnancies is obvious: neonatal complications have been found to be more common in 
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children born as a result of multiple pregnancies. To address this issue of multiple 
pregnancies in ART, several suggestions and guidelines have been implemented. It is 
now well understood that single embryo transfer is the ultimate goal in ART to reduce 
multiple pregnancies. Sweden and other European countries have introduced 
mandatory or voluntarily regulatory procedures that insist on single embryo transfer (de 
Mouzon, Goossens et al. 2012).  
To make single embryo transfer feasible, reliable methods to select the embryo with the 
most potential for implantation is needed. To date the most common way of selecting 
embryos for transfer is by morphology (Ziebe, Petersen et al. 1997; Ebner, Moser et al. 
2003; Scott 2003; 2011). Recently, time-lapse imaging has emerged as a non-invasive 
embryo selection technique (Campbell, Fishel et al. 2013; Kirkegaard, Kesmodel et al. 
2013; Montag, Toth et al. 2013). Despite improvements of stimulation protocols, 
culture media formulations and laboratory protocols, the success rate after human IVF 
treatment remain disappointingly low. Therefore, to improve implantation and thus 
success rates is to design culture media supplemented with growth factors and to 
improve cryopreservation methodology, since the ability to successfully cryopreserve 
supernumerary embryos in a given IVF cycle without losing significant embryo 
viability is essential to maximize the cumulative benefit of a given treatment cycle 
(Salumets, Suikkari et al. 2006). 
 
 
1.1 In vivo fertilization 
Women are born with a defined pool of primordial oocytes which are arrested at the 
dictyate stage of meiosis I. Once a month, follicle stimulating hormone (FSH) and other 
factors stimulate the maturation of individual follicles, generating primary and 
secondary follicles. Elevated levels of estradiol cause the pituitary to release a surge of 
luteinizing hormone (LH), which promotes maturation of the dominant follicle and 
meiotic resumption of the oocyte. Following this, the dominant follicle ruptures and 
releases the mature oocyte (MII) into the fallopian tube (oviduct) for potential 
fertilization.  
At coitus, human sperm are deposited into the anterior vagina and moves to the upper 
third of the ampulla of the fallopian tube through the cervix and across the length of the 
uterus toward the oocyte. During travel through the uterus and oviduct, sperm undergo 
capacitation. The capacitated and hyper-activated sperm interact with the oocyte in 
the ampulla of the fallopian tube. Thermotactic and chemotactic gradients are involved 
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in sperm guiding towards the oocyte and motility hyperaction assist sperm in 
penetrating mucus in the tubes and the cumulus oophorus and zona pellucida (ZP) of 
the oocyte.  
Upon reaching the oocyte, the sperm penetrates the corona radiata and attaches to the 
zona pellucida, undergoes the acrosome reaction, and binds to specific receptors (ZP1, 
ZP2 and ZP3) on the oocyte plasma membrane. The membranes of the oocyte and 
sperm fuse and the whole sperm (head and tail) enter the cytoplasma in the oocyte.  
Preimplantation development is initiated as the embryo undergoes a number of cell 
divisions while being transported down the oviduct towards the uterus and prepares for 
implantation. The embryo reaches the uterus at the blastocyst stage, hatches and then 
implants into the endometrium (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Illustration of in vivo fertilization (© The Nobel Committee for Physiology 
or Medicine, provided by the Nobel Committee for Physiology or Medicine). 
 
1.2 In vitro fertilization 
In vitro fertilization (IVF) is a process by which an oocyte is fertilized by sperm 
outside the body: in vitro. Human IVF is a major treatment for infertility after other 
methods of ART have failed to achieve a successful pregnancy. IVF was initially 
 4 
developed for a group of patients with absence or dysfunction of fallopian tubes. The 
process, as developed by Robert G Edwards, involves monitoring of the woman's 
ovulatory process and retrieving of mature oocytes (MII) prior to ovulation from the 
woman's ovaries by trans-vaginal aspiration. The retrieved oocytes are placed in 
culture dishes with culture medium and incubated with processed spermatozoa in a 
laboratory.  The content of the medium promotes sperm capacitation in vitro, which is 
a necessary requirement for fertilization process. The fertilised egg (zygote) 
undergoes a number of cell divisions in vitro. The embryo is then transferred to the 
patient's uterus with the intention of establishing a successful pregnancy (Fig. 2).  
 
Figure 2. Illustration of in vitro fertilization (© The Nobel Committee for Physiology 
or Medicine, provided by the Nobel Committee for Physiology or Medicine). 
 
 
1.3  Preimplantation embryo development 
Early human development starts with fertilization of the oocyte by the sperm, resulting 
into the formation of the zygote. The zygote undergoes first mitotic division and 
cleaves into a two-cell embryo under the control of the maternal genome. Development 
continues and after 2/3 days post insemination the embryo is at four-cell stage, 
respective eight-cell stage.  At this stage the embryonic genome is activated (Braude, 
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Bolton et al. 1988; Duranthon, Watson et al. 2008). Thereafter, the embryo undergoes 
compaction which is a major change due to the formation of the epithelium and is 
considered to be the first event of morphogenic and cellular differentiation. Following 
compaction, fluid is transported into the interior of the embryo to produce a cavity 
called the blastocoele and as it expands, two cell populations are formed, the 
trophectoderm (TE), which forms the extra-embryonic tissue and the inner cell mass 
(ICM), which forms the embryo lineage. Finally, the embryo hatches and implants into 
the endometrium. 
 
 
1.3.1 Fertilization  
 
Fertilization is a well-orchestrated series of cellular events triggered following 
sperm-oocyte interaction leading to the formation of a zygote. Fusion of the 
oocyte and sperm membranes initiates activation of the fertilized oocytes 
metabolic and biosynthetic activities and thus the commencement of early 
embryonic development (Ajduk, Ilozue et al. 2011) 
 
 
1.3.2 Cleavage 
 
The zygote cleaves into a two-cell embryo at a mean of 35.6 h post insemination 
(Trounson, Mohr et al. 1982; Cummins, Breen et al. 1986). Each blastomere then 
divides repeatedly, but not in synchrony, to yield a four-cell embryo at 44 ± 1 h post-
insemination, eight-cell at 68 ± 1 post-insemination and a morula at 92 ± 2 h post-
insemination. Between the four-cell and eight-cell stage, the transition from maternal to 
embryonic gene expression occurs; therefore, all protein synthesis up to the two-cell 
stage is regulated by maternal mRNA (Braude, Bolton et al. 1988; Kidder 1992).  
 
 
 
1.3.3 Compaction 
 
At the stage of 8-16 cells, the blastomeres in the morula suddenly increase in mutual 
adhesiveness and become packed together and form a compact sphere. The highly 
compact disposition of the embryo is consolidated by tight junctions that form at the 
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outside edges of the blastomeres, sealing off the inside of the sphere, while gap 
junctions form among the connecting blastomeres enabling exchange of small 
molecules and ions. This results into the first differentiation in mammalian 
development: the separation of the trophectoderm (TE) from the inner cell mass 
(ICM) (Tarkowski and Wroblewska 1967). 
 
 
1.3.4 Blastocyst formation 
 
The blastocyst is characterized by the inner cell mass and the trophectoderm, and a 
blastocyst cavity (blastocoel). The inner cell mass gives rise to the embryo proper, the 
amnion, yolk sac and allantois, while the trophectoderm will eventually form the 
placenta. 
 
 
1.4 Human Embryonic Stem cells 
 
Embryonic stem cells (ES cells) are pluripotent stem cells derived from the inner cell 
mass of the blastocyst stage embryo and are capable of unlimited, undifferentiated 
proliferation in vitro (Evans 1981; Martin 1981; Thomson, Itskovitz-Eldor et al. 1998; 
Ying, Nichols et al. 2003; Ying, Stavridis et al. 2003). ES cells differentiate into all 
derivates of the three primary germ layers: ectoderm, endoderm, and mesoderm. 
Embryonic carcinoma (EC) cells isolated from the teratocarcinoma were previously 
used as in vitro model for early mouse development (Martin 1980). The discovery that 
EC cells harbor genetic aberrations led to the need to culture pluripotent cells directly 
from the inner cell mass of blastocysts. 1n 1981, two independent research groups 
managed to derivate embryonic stem cells (Es cells) from mouse embryos (Evans 1981; 
Martin 1981) and eventually a breakthrough was made in 1998 when researchers 
developed a method to isolate and culture human embryonic stem cells (Thomson, 
Itskovitz-Eldor et al. 1998). 
Three core transcription factors, namely Oct-4, Sox2 and Nanog play a central role in 
the regulation of pluripotency and self-renewal in ES cells. These transcription factors 
are highly expressed in pluripotent cells and are considered markers of ES cells 
(Rosner, Vigano et al. 1990; Scholer, Ruppert et al. 1990; Avilion, Nicolis et al. 
2003; Chambers, Colby et al. 2003). They are capable of inducing the expression of 
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each other, and are essential for maintaining the self-renewing undifferentiated state 
of the inner cell mass of the blastocyst, as well as in embryonic stem cells (Rodda, 
Chew et al. 2005).  
Recently, it was shown that ES cells can be derived from single blastomeres without 
destroying the embryo (Klimanskaya, Chung et al. 2006). In 2006, it was reported 
that cells similar to ES cells can be generated by genetically reprogramming 
specialized adult cells (Takahashi and Yamanaka 2006). 
Oct-4 together with Sox2, Klf4 and often c-Myc in mouse are the transcription factors 
used to create induced pluripotent stem cells, (Maherali, Sridharan et al. 2007; Okita, 
Ichisaka et al. 2007; Wernig, Meissner et al. 2007; Yu, Vodyanik et al. 2007). It was 
later shown that only two of these four factors, Oct-4 and Klf4 were sufficient to 
reprogram mouse adult neural stem cells (Kim, Zaehres et al. 2008). Finally, it was 
shown that Oct-4 alone was sufficient for this transformation (Kim, Sebastiano et al. 
2009).  
Human embryonic stem cells (ES) and induced pluripotent stem cells (iPSCs) have 
the ability to differentiate into various cell types, therefore useful for regenerative 
medicine. 
 
1.4.1 Oct-4 
 
The Oct-4 gene (octamer-binding transcription factor 4) is a homeodomain 
transcription factor of the POU family. This protein is critically involved in the self-
renewal of undifferentiated embryonic stem cells. As such, it is frequently used as a 
maker for undifferentiated cells. Oct-4 transcription factor is initially active as a 
maternal factor in the oocyte but is expressed constitutively throughout the pre-
implantation period   (Kimber, Sneddon et al. 2008).  Oct-4 is expressed in both ESCs 
and embryonic carcinoma cells (Okamoto, Okazawa et al. 1990; Rosner, Vigano et al. 
1990; Scholer, Ruppert et al. 1990; Yeom, Fuhrmann et al. 1996) and is considered to 
be essential for pluripotency (Nichols, Zevnik et al. 1998; Niwa, Miyazaki et al. 2000). 
Deletion of the Oct-4 gene allows blastocyst formation but failure as regards 
pluripotency, which results in differentiation into a trophectodermal lineage (Nichols, 
Zevnik et al. 1998). 
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1.4.2 Nanog 
 
Nanog is a recently described homeodomain-bearing protein. It is a transcription factor 
critically involved with self-renewal of undifferentiated embryonic stem cells and has 
been described in mouse pluripotent cells (Chambers, Colby et al. 2003; Mitsui, 
Tokuzawa et al. 2003). Nanog is expressed in a restricted number of cell types and only 
in cells that also express Oct-4, including ESCs (Chambers and Smith 2004; Zhang, 
Zucchelli et al. 2009; Hambiliki, Strom et al. 2012). In the mouse embryo, Nanog is 
localized in the centre of the morula and in the ICM of the blastocyst (Chambers, Colby 
et al. 2003). Nanog-induced self-renewal and nanog function, but not nanog expression, 
are dependent on continued Oct-4 expression. Oct-4 is required for nanog-induced self-
renewal (Chambers, Colby et al. 2003; Mitsui, Tokuzawa et al. 2003; Kuroda, Tada et 
al. 2005). Genetic deletion of nanog in mouse ESCs resulted in the production of 
primitive endoderm-like cells, and nanog mutant embryos were able to produce parietal 
endoderm. Since embryos lacking Oct-4 are unable to develop so far this resulted in the 
assumption that nanog function is critical during a later developmental stage than is the 
case for Oct-4, and NANOG has been shown to be expressed from the 4-cell stage 
onwards (Kimber, Sneddon et al. 2008; Hambiliki, Strom et al. 2012). Following 
implantation, when the ICM is developing into epiblast and primitive endoderm, nanog 
is expressed in the epiblast cells (Hart, Hartley et al. 2004). 
 
 
1.5 Cryopreservation 
 
The use of ovarian stimulation of multiple dominant follicles has not only improved 
and simplified human IVF, but also led to the recovery of large numbers of oocytes 
obtained from one single oocyte retrieval (Tan, Kingsland et al. 1992). In order to limit 
the risk of high order multiple pregnancies and the associated obstetrical and perinatal 
complications and to avoid wastage of supernumerary embryos, the development of 
human embryo cryopreservation was initiated.  
Cryopreservation is a process where cells or whole tissues are cooled and stored at 
temperatures where all metabolic processes are arrested. In 1972 the first mammal 
(rabbit) was born after the transfer of frozen-thawed morulae (Whittingham, Leibo et 
al. 1972). Since then, mammalian embryos of several species have been successfully 
frozen and stored.  
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The first human embryos were frozen in the late 1970s and the first clinical pregnancy 
derived from frozen-thawed human embryos was reported in 1983 (Trounson and Mohr 
1983). The following year in 1984, the birth of Zoe Leyland was reported as the first 
birth following transfer of frozen-thawed embryos (Zeilmaker, Alberda et al. 1984). 
Since then cryopreservation of supernumerary embryos and transfer of thawed 
cryopreserved embryos in a subsequent cycle is now an indispensable part of human 
IVF.  
Cryopreservation offers several important benefits in human IVF; it allows storage of 
good quality embryos for future use (Zeilmaker, Alberda et al. 1984), thus minimizing 
the risk of transfer of more embryos than currently needed. Cryopreservation protocols 
have been optimized and simplified by use of cryoprotectants like propanediol and 
sucrose for pronucleate oocytes and early cleaved embryos (Lassalle, Testart et al. 
1985) and glycerol and sucrose for blastocysts (Cohen, Simons et al. 1985; Fehilly, 
Cohen et al. 1985; Hartshorne, Elder et al. 1991; Menezo, Nicollet et al. 1992). 
Currently, two basic types of cryopreservation are used irrespective of cell or tissue 
type: Equilibrium freezing protocols (slow freezing) and non-equilibrium protocols 
(vitrification/ultra-rapid freezing) 
 
 
1.5.1 Slow freezing 
 
Slow programmable freezing is a set of well-established techniques developed during 
the early 1970s which enabled the first birth from a human frozen embryo, Zoe 
Leyland, in 1984 (Zeilmaker, Alberda et al. 1984). Since then, most IVF programs 
use programmable machines to freeze human embryos before they are cryopreserved 
in liquid nitrogen. 
Slow freezing includes dehydration of the embryo to prevent formation of 
intracellular ice crystals. In an isotonic medium, the formation of ice crystals takes 
place between -5
0
C to -15
0
C. The formation of ice crystals may cause mechanical 
damage to the embryo by disrupting and displacing organelles, or by slicing through 
membranes (Watson and Morris 1987). This is why slow freezing techniques use 
cryoprotectants and controlled ice formation at critical temperatures. The 
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cryoprotectants commonly used in slow freezing are dimethyl sulfoxide (DMSO), 
glycerol and propanediol (PrOH).  
 
1.5.2 Vitrification 
 
The purpose of vitrification is to protect the cell by avoiding ice crystal formation. This 
is achieved by the addition of cryoprotectants at high concentrations prior to freezing.  
Vitrification was first introduced to reproductive cryopreservation in the mid-1980s 
(Rall and Fahy 1985). The applications and advantages of vitrification over slow 
freezing are increasingly clear. The method is fast and does not require expensive 
equipment. DMSO is the most frequently used cryoprotectant in vitrification protocols. 
It is a permeating cryoprotectant which protects cells from intracellular ice crystal 
formation when used at high concentrations. Recent publications show that vitrification 
of human embryos is possible with different cryoprotectant solutions, such as DMSO in 
combination with ethylene glycol (EG), or EG alone (Rama Raju, Haranath et al. 2005; 
Takahashi, Mukaida et al. 2005; Desai, Blackmon et al. 2007). 
  
 
1.6 Culture media 
 
The possibility to study mammalian preimplantation embryo in vitro became a reality 
when rabbit oocytes matured in vitro, reached the metaphase stage of meiosis II (Pincus 
and Enzmann 1935). In 1953 it was reported that eight-cell mouse embryos could 
development into blastocyst when cultured in a simple chemically defined medium 
(Whitten 1956) and that blastocyts produced in this way could develop into normal 
young after being transferred into the uterus of mouse surrogate mothers  (Mc and 
Biggers 1958). Further experiments showed that  in vitro matured rabbit oocytes could 
be fertilized in vitro and give rise to viable offspring when transferred back to adult 
females (Chang 1959). 
 Despite these advances, no progress had at that time been made regarding human in 
vitro fertilization of oocytes. A breakthrough was made when it was reported that 
human oocytes required 24 hours of incubation in vitro, before they would initiate their 
maturation process (Edwards 1965; Edwards 1965). Finally in 1969 it was shown that 
activated human spermatozoa could promote fertilization of in vitro matured oocytes 
(Edwards, Bavister et al. 1969). Edwards later reported that in vitro fertilization of pre-
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ovulatory oocytes using in vitro activated spermatozoa could give rise to eight-cell 
(Bolton, Wren et al. 1991) stage embryos and undergo further cleavage to blastocysts in 
vitro (Edwards, Steptoe et al. 1970; Steptoe, Edwards et al. 1971). These discoveries 
opened the way for human IVF which culminated in the birth of Louise Joy Brown, 
July 25, 1978 (Steptoe and Edwards 1978).  
Since then, the culture conditions for human embryos have improved considerable, 
increasing the viability of in vitro fertilized embryos. Initially, media for culture of 
human embryos to day 2 or day 3 post-insemination were simple media such as T6 
(Trounson, Leeton et al. 1980), HTF (Quinn, Kerin et al. 1985) and EBSS (Edwards 
1981). These media were composed of balanced salt solutions with added 
carbohydrates (glucose, pyruvate, and lactate) and a serum additive. However, they 
lacked important regulators of embryo development to support culture to blastocyst 
stage (Lopata and Hay 1989; Bolton, Wren et al. 1991).  
The media used for embryo culture contain ionic components (Na
+
, K
+
, Ca
2+
, Mg
2+
, 
PO4
3-
 and Cl
-
) detected in the oviduct and uterine fluids (Borland, Biggers et al. 1980), 
in a bicarbonate buffered (HCO3
-
) isotonic atmosphere. Together with water they 
contribute to the osmolarity of culture media which ranges from 250 – 290 mOsmols at 
which embryo development is supported (Brinster 1965; McKiernan and Bavister 
1990). 
The main energy substrates in culture media are pyruvate, glucose and lactate. These 
energy substrates regulate mammalian embryo metabolism in a stage-specific manner 
since early human embryo metabolism differs between pre- and post- compaction stage 
(Gardner and Lane 1997).  While, pyruvate has been shown to be essential for the early 
pre-implantation embryo (Conaghan, Handyside et al. 1993; Conaghan, Hardy et al. 
1998), glucose in association with phosphate and in the absent of amino acids has been 
shown to cause developmental delay or arrest in cleavage stage embryos in non-human 
species (Bavister 1995). This led to omission of glucose in certain culture media. 
However, this omission has been shown to be non-physiological, since glucose is 
present in the oviduct and uterine fluids and the embryo utilizes glucose throughout the 
pre-implantation period via the pentose-phosphate pathway (Gardner, Lane et al. 1996). 
Amino acids are found in the fluids of the human reproductive tract (Borland, Biggers 
et al. 1980; Casslen 1987) and oocytes and embryos contain specific transport 
mechanisms for amino acids. They act as energy substrates, precursors for protein 
synthesis, osmolytes and in maintenance of intracellular pH (Gardner and Lane 1998). 
Previous studies have shown a biphasic requirement of amino acids during the 
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preimplantation period (Lane and Gardner 1997; Steeves and Gardner 1999). It has 
been shown that non-essential amino acids and glutamine stimulate cleavage rate and 
that glutamine and essential amino acids promote culture to the blastocyst stage (Lane 
and Gardner 1997; Lane, Hooper et al. 2001). Amino acids spontaneously break down 
at 37
o
C and release ammonium which is toxic for the embryo even at low 
concentrations because ammonium retards embryo development, foetal growth and 
increases the incidence of neural tube defects (Gardner and Lane 1993). Ammonium 
can significantly be reduced if glutamate is replaced with the more stable alanyl-
glutamine or glycyl-glutamin (Lane, Hooper et al. 2001). 
Vitamins are also key components of cellular metabolism and are thus added in culture 
media. It has been shown that they have significant effects on embryo development of 
non-human species (Kane and Bavister 1988; Tsai and Gardner 1994; McKiernan and 
Bavister 2000). However, no benefits of vitamins on the human embryo have been 
shown (Tarin, de los Santos et al. 1994).  
EDTA is added to culture medium for its potential as a chelating agent of metal ions 
and has beneficial effects on the cleavage stage mouse embryo (Gardner and Lane 
1996; Gardner, Lane et al. 2000). However, EDTA should not be included in media 
intended for culture of post-compaction stage embryos as it inhibits the development of 
inner cell mass (Lane and Gardner 1997).  
Protein sources in the form of serum or albumin in culture media play a role as organic 
osmolytes and pH buffers. In the IVF lab they prevent embryos from adhering to 
pipettes or plastic containers for tissue culture. There are several risks associated with 
addition of patient serum in culture media like potential viral transmission (Ashwood-
Smith, Hollands et al. 1989), negative effects on embryo development (Lopata and Hay 
1989; Dokras, Sargent et al. 1993; Ito, Fujino et al. 1996), trophectodermal (Mortell, 
Marmorstein et al. 1993) and mitochondrial deterioration (Thompson, Gardner et al. 
1995) and metabolic perturbations (Gardner 1994). This has led to the use of 
chemically defined alternatives to human sera such as purified albumin (Ashwood-
Smith, Hollands et al. 1989) and  recombinant serum albumin (Lane, Hooper et al. 
2001). 
Hyaluronan is another macromolecule included in culture media. It is present in the 
female reproductive tract and its use has been shown to improve implantation rates 
(Gardner, Rodriegez-Martinez et al. 1999; Hambiliki, Ljunger et al. 2010) and increase 
survival after freezing, of blastocyts (Gardner, Rodriegez-Martinez et al. 1999). 
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Increased understanding of both the physiology of the embryo and the environment of 
the oviduct and uterus has led to two different approaches for design of ART specific 
culture media: the `back to nature´ approach (sequential culture media) and the ´let the 
embryo choose´ approach (monoculture). Both media reflect the change in 
concentrations of metabolites from the oviduct fluid to uterine fluid.  
There is a need for optimization of culture conditions to enhance implantation, despite 
significant improvements since the inception of IVF. Co-culture systems and 
supplementation of growth factors in culture media are among such strategies to 
improve culture media. 
Co-culture of human embryos with somatic cells was shown to support development of 
embryos to the blastocyst stage (Menezo, Guerin et al. 1990; Wiemer, Hoffman et al. 
1993; Hu, Maxson et al. 1998; Wetzels, Bastiaans et al. 1998) and improve pregnancy 
rates (Menezo, Hazout et al. 1992; Freeman, Whitworth et al. 1995; Ben-Chetrit, 
Jurisicova et al. 1996), especially in patients with repeated IVF failures (Bongso, Ng et 
al. 1991; Olivennes, Hazout et al. 1994). Somatic cells may benefit embryo 
development by providing trophic factors and/or by modifying inhibitory media 
components (Bongso, Ng et al. 1991; Edwards, Batt et al. 1997; Liu, Chan et al. 1998).  
 
1.6.1 Growth factors 
 
Growth factors have been identified in the female reproductive tract fluid and receptors 
are present on epithelial cells of the oviduct and the uterus. Supplementation of culture 
media with growth factors such as leukaemia inhibitory factor (LIF) (Dunglison, 
Barlow et al. 1996), heparin binding-epidermal growth factor (EGF) (Martin, Barlow et 
al. 1998),  transforming growth factor alpha (TGF-alpha) (Paria and Dey 1990), 
granulocyte-macrophage colony stimulating factor (GM-CSF) (Sjoblom, Wikland et al. 
1999), has been shown to increase development of human embryos to blastocyst stage. 
 
1.6.2  Leukemia inhibitory factor (LIF) 
 
Leukaemia Inhibitory Factor (LIF) is an interleukin 6 class cytokine that affects cell 
growth and cell differentiation of different types of target cells in the embryo as well as 
in the adult (Gearing 1993), such as embryonic stem cells (Smith, Nichols et al. 1992), 
primordial germ cells (Matsui, Toksoz et al. 1991) and peripherial neurons (Yamamori 
1992). LIF has been shown to be involved in a number of processes in reproduction 
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such as enhancement of sperm motility and survival (Attar, Ozsait et al. 2003) and in 
the physiology of ovulation (Arici, Oral et al. 1997). LIF enhances blastocyst formation 
and hatching (Lavranos, Rathjen et al. 1995) and has been shown to be essential for 
implantation in mouse (Stewart, Kaspar et al. 1992). LIF also increases implantation 
rates in sheep (Fry, Batt et al. 1992). It is known that addition of LIF to the culture 
medium significantly increases blastocyst formation in human embryos (Dunglison, 
Barlow et al. 1996).  
The importance of LIF in human implantation is still uncertain. In the endometrium of 
healthy women, LIF receptor (LIFR) and glycoprotein 130 (gp130) are expressed 
throughout the cycle with strong increase in the midsecretory phase, coinciding with a 
supposed window of implantation. It has been observed that the endometrium in 
infertile women produces significantly less LIF during the period of receptivity than in 
women with proven fertility (Laird, Tuckerman et al. 1997; Hambartsoumian 1998; 
Lass, Weiser et al. 2001). This has led to the suggestion that recombinant human LIF 
might help to improve the implantation rate in women with unexplained infertility 
(Aghajanova, Skottman et al. 2006). 
However, the LIF content in uterine secretion at the time of oocyte retrieval does not 
seem to be correlated to pregnancy rate (Olivennes, Ledee-Bataille et al. 2003). LIF 
exerts its biological effects by interaction through its specific LIF receptor (LIFR). The 
LIFR forms a high affinity heterodimer complex with gp130 (Robinson, Grey et al. 
1994). Expression of mRNA activity for LIFR and gp130 has been demonstrated in 
human preimplantation embryos (Sharkey, Dellow et al. 1995; Chen, Shew et al. 1999), 
but the localization of LIFR and gp130 in human preimplantation embryos has to our 
knowledge not been reported.  
LIF is produced in the human Fallopian tube. The highest levels are seen in the luminal 
epithelium of the ampulla, where the embryo first develops before its transport into the 
uterine cavity for implantation (Keltz, Attar et al. 1996; Li, Sun et al. 2004). Co-culture 
of mouse embryos with human oviductal cells will result in maintained mitochondrial 
function, decreased apoptosis in the embryo and a higher degree of blastocyst 
formation and hatching (Xu, Cheung et al. 2000; Xu, Cheung et al. 2001; Xu, Chan et 
al. 2003). Cultured bovine oviductal cells synthesize LIF that conditions the embryo for 
implantation (Reinhart, Dubey et al. 1998).  
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1.6.3 Leukemia inhibitory factor receptor (LIFR) 
 
Leukemia inhibitory factor receptor (LIFR) is a subunit of a receptor for leukemia 
inhibitory factor. LIF action appears to be mediated through a high-affinity receptor 
complex composed of a low-affinity LIF binding chain (LIF receptor) and a high-
affinity converter subunit, gp130. The expression of LIF and its receptor in human 
endometrium increases around the time of implantation and was demonstrated to 
appear simultaneously with pinopodes (Aghajanova, Stavreus-Evers et al. 2003). LIF is 
believed to be a regulatory factor essential for implantation of the blastocyst through 
autocrine and paracrine interaction between LIF and its receptor in the luminal 
epithelium (Cullinan, Abbondanzo et al. 1996; Cheng, Rodriguez et al. 2002). 
 
1.6.4 Glycoprotein 130 
 
Glycoprotein 130 (gp130) is a trans-membrane protein which is the founding member 
of the class of all cytokine receptors. It forms one subunit of type I cytokine cytokine 
receptors within the IL-6 receptor family and is important for signal transduction. The 
gp130 trans-membrane subunit can also, as a monomer, act as interleukin-6 (IL-6), 
interleukin-11 (IL-11) and ciliary neutrophic factor (CNTF) receptor (Auernhammer 
and Melmed 2000).  
Gp130 is most abundantly expressed at the time of implantation (Classen-Linke, 
Muller-Newen et al. 2004), when increased secretion of soluble gp130 was seen 
(Sherwin, Smith et al. 2002). LIFR and gp130 mRNA is also expressed in the decidua 
and may play a key role during the decidualization and placentation (Ni, Ding et al. 
2002). It has been shown that the secretion of gp130 was reduced in infertile women 
(Sherwin, Smith et al. 2002). 
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2 Aims of the studies 
 
The general aim of the current thesis was to study different aspects of embryo 
development such as culture, cryopreservation and characterization in relation to in 
vitro fertilization. 
 
Accordingly, the studies had the following aims: 
 
 To compare the effects of two different sequential culture media on embryo quality. 
 
 To investigate the effect of growth factors (LIF and gp130) on embryo 
development.   
 
 To compare two vitrification protocols with and without DMSO. 
 
 To localize transcription factors (NANOG and OCT4) in human pre-implantation 
embryos and in human embryonic stem cells.  
 
 To investigate the regulation of LIF and gp130 receptors by P in the human 
Fallopian tube and the endometrium, and their localization in the pre-implantation 
embryo. 
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3 Materials and methods 
 
3.1 Ethics aspects 
Approval was obtained for the studies presented in this thesis from the Ethics 
committees at Karolinska Institutet, Uppsala University and Örebro University. The 
human embryos were donated for research after their 5-year storage limit has passed. 
The donors of the embryos did not receive any financial reimbursement. The women 
who donated fallopian tube and endometrial tissue gave their informed consent to 
participate in the study. The invasive procedures performed were not considered to 
have any negative effect of significance for the women. 
 
 
3.2 Study materials 
 
Human oocytes (article I) were collected from women undergoing IVF treatment at the 
Centre for Reproduction, Uppsala University Hospital, Sweden. Human embryos 
(article II, III, IV and V) were donated with informed consent by couples undergoing 
IVF treatment at Karolinska University Hospital/Huddinge, Uppsala University 
Hospital and Örebro University Hospital. Mouse embryos, (article III), were obtained 
from Embryotech (www.embryotech.com). Fallopian tube and endometrial tissue 
(article V) were obtained from healthy women undergoing sterilization at Karolinska 
University Hospital. Table 1 summarizes the materials used in the five articles 
presented.  
 
Table I Information of samples used in the five studies 
 
Sample  Sample number Sample source Article location 
Oocytes 1206 IVF patients I 
Human 
embryos 
465 
 
Donated by IVF patients II, III, VI, V 
Mouse 
embryos 
240 Embryotech  III 
Biopsies 22 Healthy women undergoing 
sterilization 
V 
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3.3 Methods 
The details of the different methods in this thesis are described in the studies in which 
they are used. In this section, the basic principles for the techniques are outlined, and 
limitations and advantages of the methods are discussed. Table 2 summarizes the 
methods used in the respective articles. 
 
Table 2 List of methods used in the different studies 
 
Method Article location  
Embryo culture I, II, III, IV 
Assessment of embryos  I, II, III, IV V 
Cryopreservation of embryos I, II, III, IV V 
In situ hybridization III 
Immunohistochemistry II, III, IV V 
MALDI TOF MS  II 
 
 
3.4 Embryo culture  
 
Following IVF or ICSI, oocytes were cultured individually in 20 μL droplets of culture 
media under mineral oil. Culture was performed at 37 °C and 6 % CO2. In all studies, 
the culture conditions were kept identical as regards to temperature and pH.  Embryos 
of good quality were either used for direct embryo transfer on day 2 or day 3, or frozen 
for later use by the patient (supernumerary embryos). 
 
Considerations 
First, it must be stressed that before making any comments about the impact of embryo 
culture medium on embryo development in vitro, all aspects of the culture system 
(laboratory and quality procedures) should be optimised.  
Human pre-implantation embryos are sensitive to changes in culture milieu. In order to 
keep the culture conditions as constant as possible, commercial media was used 
throughout the studies. The embryos were cultured in the media currently used at the 
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clinic. The advantages of using commercial media instead of home-made media are 
pragmatic: they are reproducible at different times and in different laboratories, they 
undergo stringent quality control procedures and tests on each batch before release, and 
they are free of unknown activities that may interfere with the responses being studied. 
The main disadvantage of commercial media is that the exact composition of the 
solution is still kept as a company secret.  It would be of great interest for culture media 
research if the culture media companies released the exact formulation of culture 
media. This would allow researchers to carry out experiments on the effect of specific 
components on embryo development that are reproducible by other researchers. 
 
3.5 Assessment of embryos  
 
On the morning of day 2 or day 3, embryo quality was assessed morphologically on the 
basis of the number of blastomeres (cells), fragmentation rate (volume of embryo with 
anucleate fragments) and multinucleation of blastomeres equivalent to the guide lines 
published by Alpha and ESHRE (Prados, Debrock et al. 2012).  Embryos were 
regarded as of ‘good quality’ when they were at the 4-cell stage after approximately 
46 h post insemination (day 2) or at the 8-cell stage, approximately 70 h post 
insemination (day 3) and had a score of 0–2.  
Blastocyst stage embryos were scored strictly according to the guidelines published 
previously (Gardner, Lane et al. 2000) and by Alpha and ESHRE (Hardarson, Van 
Landuyt et al. 2012). In brief, the blastocyst is assessed on the basis of three 
parameters: blastocyst expansion and hatching status, the quality of the inner cell mass 
(ICM), and the quality of the trophectoderm (TE), based upon cell number and 
cohesion. A good quality blastocyst was classified as one with a distinct inner cell mass 
(ICM), a well-differentiated trophectoderm (TE), and a single large blastocoele cavity 
without degenerative foci on day 5/6 of development and had a score of at least 3BB. 
 
Considerations 
The evaluation of embryos was performed under light microscope. It is of interest to 
note that this kind of assessment of embryos only gives a score of the morphology of 
the embryo, and does not accurately reflect developmental potential of an embryo. New 
non-invasive methods for evaluating embryos could improve IVF success rates. Using 
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time-lapse videography, researchers have discovered characteristics that predict 
successful development to blastocyst stage (Wong, Loewke et al. 2010). 
 
3.6 Cryopreservation of embryos 
 
Cryopreservation of embryos is the process of preserving an embryo at temperatures 
where all metabolic processes are arrested. It involves two stages: freezing and 
thawing. Objectives of cryopreservation are to avoid the formation of intracellular ice 
crystals, which can lead to cell damage and developmental arrest (Shaw and Jones 
2003). To overcome this problem two cryopreservation protocols have developed, slow 
freezing and vitrification. In slow freezing the growth of intracellular ice crystals is 
avoided by controlling the cooling rate of the embryo and its surrounding environment 
with the use of cryoprotectants at low concentrations. Supernumerary embryos were 
cryopreserved on day 2 according to a controlled slow freezing protocol including the 
cryoprotectants 1, 2 propanediol and sucrose in phosphate-buffered saline (PBS).   
The thawing of embryos was performed using a commercial kit. The embryos were 
then transferred into equilibrated culture medium and carefully assessed for blastomere 
survival. Each embryo received a score of A (100% survival rate), B (50% ≤ survival 
rate < 100%), or C (<50% survival rate). Only embryos with a score of A or B were 
used in the studies. The embryos were then randomly allocated, with regard to embryo 
morphology/survival rate, into different treatment regimens and cultured up to 
blastocyst stage.  
During vitrification, the embryo and the surrounding solution directly solidify to a 
glasslike state. Use of high concentrations of cryoprotectants and rapid cooling rates, 
eliminates both extracellular and intracellular ice crystal formation (Liebermann, 
Nawroth et al. 2002).  
The vitrification protocol was performed at room temperature. Briefly, the embryos 
were rinsed and transferred to vitrification solution (with or without DMSO). One to 
three embryos were loaded on a cryloop and plunged into liquid nitrogen. 
The warming of embryos was performed at room temperature. The cryoloop was 
placed directly and quickly into warming solution and the embryos were there after 
cultured to blastocyst stage according to standard procedures.  
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Considerations 
 
Controlled ice formation during freezing is recognized as to be a key factor in 
determining the viability of embryos following freezing and thawing. Even if high 
survival rates are observed after vitrification and warming, we observed low survival 
rates in our study (article III). This could be due to the extended culture and definition 
of survival used. We defined survival as the percentage of embryos that continued to 
develop to the blastocyst stage in vitro. 
 
3.7 In situ hybridization (ISH) 
 
In situ hybridization was used to detect the presence of NANOG mRNA in human 
preimplantation embryos and human embryonic stem cells.  
 
Considerations 
In situ hybridization is a versatile tool for the examination/localization of gene 
expression. It detects a hybridized labeled nucleic acid probe (RNA or DNA) to a 
complementary sequence of mRNA. The method is extremely sensitive and can detect 
the amount of mRNA in a single cell. Its major advantage is that it allows the 
maximum use of rare tissues like human embryos. Another method we may have 
considered using is single cell reverse transcription (RT-PCR). It is more sensitive than 
ISH, but it has the disadvantage that one cannot locate the mRNA of interest. 
 
3.8 Immunohistochemistry (IHC) 
 
IHC was used to show the presence of specific proteins in human embryos and hESCs. 
In addition, immunohistochemistry was also used to detect apoptosis and damage to 
the cytoskeleton.  
 
Considerations 
Immunohistochemistry or IHC is a method that exploits the antibody binding to 
specific antigens. The advantages of IHC are that the localization of the protein is 
shown. However, lack of specificity, difficult of interpretation and low percentage of 
reproducibility are the major draw backs of IHC. We used monoclonal antibodies for 
consistency and standardization of experimental procedures and results. 
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3.9 MALDI TOF MS 
 
Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI 
TOF MS) was used for direct protein profiling of intact blastocysts. It is a robust 
method in which a co-precipitate of an UV-light absorbing matrix and a biomolecule is 
irradiated by a nanosecond laser pulse. The ionized biomolecules are accelerated in an 
electric field and enter the flight tube. During the flight in this tube, different molecules 
are separated according to their mass to charge ratio and reach the detector at different 
times. In this way each molecule yields a distinct signal.  
 
Considerations 
The advantage of using MALDI TOF MS for detection and characterization of 
biomolecules, such as proteins and peptides, is that it is a relatively fast method with 
short measuring time and negligible sample consumption. This is important since 
human embryos for research are scarce. 
 
3.10  Statistical analysis 
 
SPSS statistical software (Chicago, II, USA) was used to calculate statistics. The 
Fisher’s exact test (two-tailed) and Chi-square test were used to test differences 
between groups in articles I, III, and IV.  Nonparametric statistical evaluation, ANOVA 
on ranks, was performed for differences in staining intensity for LIFR and gp130. 
Mann–Whitney Rank Sum Test was performed to compare the mRNA levels. A P-
value of < 0.05 was considered statistically significant. 
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4 Results and discussion 
 
4.1 Culture and vitrification media 
The goal of embryo culture in human IVF is to improve the quality of embryos in vitro 
and the chances of successful delivery of a healthy baby.  
In article I, we investigated the impact of culture media on embryo morphology and 
development at days 2/3. A total of 1206 oocytes from 110 women were analysed. 
The average age (+/-SD) of the patients was 39.9 ± 3.8 (range 24 – 40) years. Sibling 
oocytes were divided via alternate allocation to fertilization and culture in media 
system A (G-IVF 
TM
 v5 PLUS/ G-1
TM
 v5 PLUS) or for fertilization and culture in 
media system B (Universal IVF medium/EmbryoAssist 
TM
). The main results were 
that normal fertilization rate and embryo utilization rate was significantly higher in 
group A than in group B (73.5% and 55.5% compared with 67.2% and 42.9% 
respectively, p = 0.030 and p = 0.001). No difference was seen regarding polyploidy 
and embryo quality between the two groups (Table 3).  
Table 3 Outcome of 1206 sibling oocytes assigned to media system A or system B. 
*statistically significant (p < 0.05, Chi-square test) 
 Media A Media  B P-value 
Number of oocytes inseminated, n 622 584 0.122 
Mature oocytes (MII), n (%) 520 (83.6) 469 (80.3) 0.137 
Normal fertilized oocytes (2PN), n (%) 382 (73.5) 315 (67.2) 0.030
*
 
Polyploid (>2PN), n (%) 29 (5.6) 34 (7.3) 0.282 
Embryo quality (grade 0–2)     
with 4-cells at day 2, n (%) 210 (54.9) 163 (52.7) 0.396 
with 8-cells at day 3, n (%) 23 (6.0) 11 (3.5) 0.123 
Embryos cryopreserved, n (%) 124 (32.5) 111(35.2) 0.439 
Embryo utilization, n (%) 212 (55.5) 135 (42.9) 0.001
*
 
 
We have shown that culture media has impact on fertilization, embryo morphology 
and development at days 2/3. The components of the two culture media systems differ 
and detailed composition of the media is unknown, which makes it difficult to 
determine exactly which ingredients are the most optimal for embryo culture. The 
difference in fertilization rate between the two groups can possibly be due to the fact 
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that media A contains components known to be beneficial for fertilization like lactate 
(Kito and Ohta 2008), EDTA (Abramczuk, Solter et al. 1977; Mehta and Kiessling 
1990) and taurine (Devreker and Hardy 1997). Furthermore, fertilization medium A 
contains a number of defined amino acids while fertilization medium B lacks amino 
acids. However, these differences may have been overcome if embryos were cultured 
to the blastocyst stage.  
In summary, this study showed that today’s culture media is far from optimal for 
supporting embryos in vitro. Our study confirms previous studies that have suggested 
that culture media have an impact on embryo quality in vitro (Cooke, Quinn et al. 
2002). Furthermore, the effect of culture media on embryo quality has recently been 
reviewed by Mantikou et al were it was concluded that current culture media does not 
lead to the best success results in IVF/ICSI (Mantikou, Youssef et al. 2013).  
With this in mind, we went on to conduct a study (article II) to see if addition of 
growth factors in culture media can enhance embryo development in vitro. A total 
number of 164 embryos which survived thawing were cultured in the presence of LIF 
and/or gp130 and the in vitro effect on human embryo development studied. The 
main results were that culture of embryos in media supplemented with gp130 
significantly improved blastocyst development (75%) compared to control (37%), 
LIF (41%) or LIF + gp130 (29%), respectively (Table 4).  On the other hand, LIF 
seemed to be detrimental for embryo development, which is contrary to what is seen 
in the mouse, were LIF enhanced blastocyst formation and birth rates (De Matos, 
Miller et al. 2008). We have in this study demonstrated the effect of gp130 on human 
embryo development, implicating a physiological role in regulating early embryo 
development. We, therefore, suggest that gp130 is beneficial for embryo development 
and should be included in culture media.  
Table 4 Morphological embryo development assessed by light microscope 
Treatment  No of embryos Blastocysts, n 
(%) 
High quality blastocysts, n (%) 
Total 164 73 (44) 40 (24) 
Control 43 19 (37) 10 (23) 
gp130 40 29 (73) 15 (38) 
LIF  46 19 (41) 9 (20) 
LIF + gp130 35 10 (29) 6 (17) 
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Beneficial effects of growth factors in enhancing embryo development in vitro have 
been previously demonstrated. Granulocyte-macrophage colony stimulating factor 
(GM-CSF) (Sjoblom, Wikland et al. 1999), leukaemia inhibitory factor (LIF) 
(Dunglison, Barlow et al. 1996), epidermal growth factor (EGF) (Martin, Barlow et al. 
1998) and insulin-like growth factor-1 (IGF-1) have been shown to increase blastocyst 
development in human embryos. Additionally, IGF-1 (Lighten, Moore et al. 1998) and 
GM-CSF (Sjoblom, Wikland et al. 1999) stimulated development of the inner cell 
mass. The supplementation of GM-CSF in culture media improved pregnancy rates and 
was shown to be beneficial in women with previous miscarriage (Ziebe, Loft et al. 
2013). These results and our data demonstrate the need of optimizing human embryo 
culture.  
 
Besides optimization of the media for culture, media and protocol for vitrification also 
need improvement. To maximize the potential for conception for IVF and prevent 
wastage of viable normal supernumerary embryos, cryopreservation programmes has 
become an essential part of IVF. Improving cryopreservation media would be of great 
benefit to IVF programmes. We therefore conducted a trial to evaluate different 
vitrification protocols. 
 
In this study (article III) we set out to compare two different vitrification protocols: 
one with dimethyl sulphoxide DMSO, propane-2-diol, and ethylene glycol, and a 
second protocol with only propane-2-diol, and ethylene glycol. Viability and the 
importance of specific incubation times for early embryo recovery, survival and 
cleavage were studied. The two protocols did not differ in embryo survival rates (Table 
5). However, the study showed that morphological assessment of embryos after 
vitrification was not a useful tool for survival assessment. Therefore, we recommend 
that vitrification of early embryos should be combined with extended culture before 
transferring to patients 
Additionally, we assessed cryodamage in embryos using the Vybrant Apoptosis Assay 
kit and showed that DMSO-containing vitrification solutions protect embryo membrane 
integrity than solutions without DMSO. We have shown that DMSO-containing 
vitrification solution leads to less cryodamage compared to DMSO-free vitrification 
solution, possibly due to the fast penetrating characteristics of DMSO. 
Just like this study, other researchers have previously shown that cryopreservation 
protocols can be improved to the better (Liebermann and Tucker 2004).  
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Table 5 Comparison of media with dimethyl sulphoxide DMSO) and media without 
DMSO in mouse and human model systems (Survival:  %, number survived/total 
number)  
 
 Mouse embryos Human embryos 
With DMSO 77 (43/56) 30 (16/53) 
Without DMSO 80 (45/56) 35 (28/80)  
. 
 
 
4.2 Embryo characterization 
 
The importance of characterization of embryos cultured in vitro is of great importance 
in reproductive medicine. Using molecular and biochemical techniques key factors 
important for embryo development can be detected. Part of this thesis was to deploy 
these techniques to detect/localize some of the factors involved in embryo 
development. 
 
Immunohistochemical analysis showed the presence of NANOG and OCT4 protein in 
human embryos and human embryonic stem cells (hESCs) (article IV). NANOG and 
OCT-4 were co-localized in human morula and blastocyst stage embryos. The time of 
appearance in the early morula resembled that seen in mouse embryos (Palmieri, Peter 
et al. 1994; Chambers, Colby et al. 2003; Hatano, Tada et al. 2005). We also observed 
immunostaining of OCT4 in the trophoblast cells of the blastocyst. Our results are 
confirmed by same observations in bovine blastocysts (van Eijk, van Rooijen et al. 
1999; Kirchhof, Carnwath et al. 2000). This is also in line with the results observed in 
human blastocyst showing the expression of OCT-4 mRNA (Hansis, Grifo et al. 2000). 
 
Furthermore, using whole mount in situ hybridization we localised NANOG mRNA in 
a group of cells in the morula, in cells of the ICM of blastocyst, and evenly in hESCs 
(article IV). This method gave us the unique opportunity to visualize the expression of 
NANOG in both time and space in single human embryos. 
 
Finally, we compared data from the present study with our data from gene array studies 
(Zhang, Zucchelli et al. 2009). The gene array data showed the presence of NANOG 
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mRNA in human pre-implantation embryos and hESCs (Table 6).  Nanog mRNA was 
present from day 2 and highly expressed in hESCs. OCT4, on the other hand was 
weakly expressed in human pre-implantation embryos and highly expressed in hESCs 
(Table 6). The two transcription factors were absent in fibroblast (Table 6). 
 
Table 6 Data from microarray analysis of human embryos and embryonic stem cells 
and fibroblasts. 
 
Gene Signal intensity 
 Day 2 
embryos 
Day 3 
embryos 
Day 5 
embryos 
Stem cells Fibroblasts 
Nanog 98.6 194.6 196.8 391.8 1.3 
Oct4 32.2 67.1 46.8 310.9 5.3 
 
 
In another study (article V), we looked at the presence of LIFR and gp130 in 
preimplantation embryo, the human Fallopian tube and endometrium. Using 
immunohistochemistry, LIFR and gp130 were localized in preimplantation embryo, 
Fallopian tube and endometrium.  
 
In embryos, the presence of LIFR and gp130 was shown in all pre-implantaion 
embryonic stages (Fig. 4). The presence of LIFR was more evident in the Fallopian 
tube than in the endomentrium. The higher levels of LIFR in the Fallopian tube could 
be expressed by the fact that LIFR produced by the embryo acts both within the embryo 
and with the Fallopian tube in an auto-and paracrine manner. In the blastocyst, the 
presence of gp130 was mainly located in the inner cell mass, whereas LIFR was 
expressed in all cells.  
 
We then went on to study the effect of mifepristone on the expression of LIFR and 
gp130 in the human Fallopian tube (article V). Our results showed that mifepristone 
had no effect on the expression of LIFR and gp130 in the human Fallopian tube, nor in 
endometrium suggesting that progesterone might not be involved in the regulation of 
LIFR or gp130. 
Next we obtained a characteristic protein fingerprint spectra from individual 
blastocyst. The analysis was carried out using Matrix-assisted laser 
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desorption/ionization time of flight mass spectrometry (MALDI TOF MS). Protein 
fingerprint spectra reviewed the presence of multiple common protein species like 
Ubiquitin, histone H4, thymosin beta 4 and thymosin beta 10. Due to the small size 
and limited number of human pre-embryos, little is known about the protein patterns 
of early human embryo development. Here, we demonstrate that MALDI TOF MS is 
a valuable tool for analysis of protein patterns in pre-embryos. 
Further, we confirmed some of our results from MALDI TOF MS analysis. 
Imunohistochemical staining showed the presence of ubiquitin, histone H4, thymosin 
beta 4, and thymosin beta-10 in human blastocysts. The staining reviewed that 
ubiquitin is present both in the ICM and in the trophectoderm of the blastocyst. Our 
results regarding ubiquitin are confirmed by the results in mice which showed a 
positive effect of ubiquitin in placentation (Bebington, Doherty et al. 2000), Histone 4 
was observed only in trophectodermal cells. Thymosin beta 4 was seen in ICM and 
thymosin beta 10 both in ICM and trophectoderm (Figure 3).  
 
Figure 3. Immunohistochemical staining of (A) ubiquitin, (B) histone H4, (C) 
thymosin beta 4, and (D) thymosin beta-10 in human blastocysts. Nuclear staining with 
6-diamino-2-phenylindole (DAPI) is shown in blue. 
 
 
Figure 4. Immunostaining of LIFR and gp130 in human preimplantation embryos. 
Staining for LIFR: (A) 2 cell embryo (B) 4-cell embryo. (C) 8-cell embryo (D) Morula. 
(E) Early blastocyst. (F) Expanded blastocyst. (G) Negative control. Staining for 
gp130: (H) 2-cell embryo (I) 4-cell embryo. (J) 8-cell embryo (K) Morula. (L) Early 
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blastocyst. (M) Staining of the inner cell mass in a hatching blastocyst. (N) Negative 
control. 
 
 
 
 
 
 
 
.    
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5 Summary and conclusions 
 
The current thesis gives new perspectives on culture, cryopreservation and 
characterization of human embryos in vitro. 
 
The main findings of the current thesis are: 
 
 The presence of LIFR and gp130 in the Fallopian tube and preimplantation 
embryo indicates a role for LIF in communication between the embryo and 
the Fallopian tube.  
 
 The growth factor gp130 seems to be beneficial for preimplantation embryo 
development and ought to be included in culture media designed for embryo 
culture to the blastocyst stage. 
 
 Culture media has impact on early embryo development and this endorses the 
important need for research in culture media formulation to further improve 
media for in vitro development of human embryos. 
 
 Vitrification protocols consisting of DMSO as a cryoprotectant are suitable and 
equally efficient in both mouse and human embryo models.  
 
 Molecular and biochemical analytical methods like whole mount in situ, 
immunohistochemistry and MALDI TOF MS are versatile tools in 
reproductive medicine research. 
 
Studies from animal models indicate that stressful environmental conditions like in 
vitro culture and cryopreservation may lead to epigenetic alterations. This compelling 
evidence endorses the importance of basic research in optimizing culture and 
cryopreservation conditions in order to further advance assisted reproductive 
techniques (ART) and minimize epigenetic alterations. 
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6 Future perspectives 
 
The findings in this thesis highlight three laboratory areas that warrant considerable 
discussion. 
 
The first area for future studies is the optimization of embryo culture in vitro. Culture 
media intended for use in human IVF treatment must be developed to meet the 
embryo's nutrient requirements and physiology in order to reflect the in vivo 
environment in which the zygote forms and divides. To make these feasible, 
randomized trials must be performed and components of the medium disclosed. 
Addition of growth factors to culture medium should be undertaken with care, 
considering that stressful environmental conditions may lead to epigenetic alterations. 
 
Another area of interest is non- invasive selection of viable/normal embryos for 
transfer. The development of time-lapse devices for the IVF laboratory has given 
embryologists a unique chance to observe and study human embryos in vitro. 
Proteomic and metabolomic profiling using microfluidics may also help in selecting 
embryos. These non-invasive strategies of evaluating embryos combined with the 
traditional qualitative morphological observation could help to improve IVF success 
rates and reduce multiple gestations.  
 
The third area of interest is cryopreservation of gametes and embryos. We have in this 
thesis shown that there is need for more robust and safe vitrification protocols. 
Research areas of interest are in designing protocols with very low cryoprotectans (< 
1M) and in improving devices to obtain super high cooling rates.  
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Abstract
Purpose Although several media systems have been devel-
oped, data from prospective randomised clinical studies are
still lacking. In the present study we compared the effects
of 2 different media systems on embryo morphology and
development at days 2/3 using sibling oocytes.
Methods In this prospective sibling-split trial, 1206 oocytes
from 110 women were divided via alternate allocation to
fertilization and culture in media system A (G-IVF TM v5
PLUS/ G-1TM v5 PLUS) or for fertilization and culture in
media system B (Universal IVF medium/EmbryoAssist TM).
Results The use of media systemA significantly increased the
normal fertilization rate (73.5% versus 67.2%; p=0.030) and
embryo utilization rate (55.5% versus 42.9%; p=0.001),
whereas polyploidy and embryo quality were similar in the
two groups.
Conclusion The different impacts on fertilization and early
embryo development between the two commercially avail-
able and commonly used media systems show the impor-
tance of evaluation of the efficacy of existing sequential
culture media and the need to further improve media for in
vitro development of human embryos.
Keywords Sibling oocytes . Culture media . Fertilization
rate
Background
The human oocyte is fertilized in the Fallopian tube and
is developing during the transport into the uterus, where
it is implanted at the blastocyst stage [1–3]. The ampulla
region of the Fallopian is the natural environment for
fertilization and the first mitotic divisions occurs as the
pre-embryo passes along the Fallopian tube to reach the
uterus [3]. The in vivo environment is optimal for the
developing preimplantation embryo as it moves and
develops along this route. Media intended for use in IVF
treatment should be optimised in order to reflect the
environment in the Fallopian tube and endometrium, as
the culture conditions in which the zygote forms and
divides plays an important part in dictating its develop-
ment and subsequent achievement of a successful preg-
nancy [4]. The change in environment in the different
parts of the Fallopian tube has lead to development of
different culture media systems.
Development of new culture media is continuously
ongoing, but so far none of the media used are as complex
as the tubal and endometrial fluid. Simple media has
gradually been replaced with more complex culture
systems; but the ability of different media to support the
fertilization and culture of preimplantation embryos up to
cleavage stage remains uncertain [5]. Although the use of
commercial media is usually beneficial [6], these media are
still under investigation and their most optimal composition
remains to be determined.
The aim of the present study was to compare the effects
of two different commercial culture media on early embryo
Capsule Two commercially available and commonly used media
systems show different impacts on fertilization and early embryo
development
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development using a prospective randomized sibling
design. The primary outcome measure was normal fertil-
ization rate. The secondary outcome measures were
polyploidy rate, embryo utilization rate and embryo quality
(EQ) at day 2 and 3.
Material and methods
Design of the study
This trial was designed as a prospective randomized sibling
oocyte split study and included all oocytes from women
undergoing IVF treatment at the Centre for Reproduction,
Uppsala University Hospital, Sweden, between October 2007
and December 2007. The age limits of the patients ranged
from 24 to 40 years, with a mean (± SD) of 33.9±3.8 years.
The oocytes were randomly allocated into one of two groups
at the time of ovum pick up. Allocation was not blinded.
Oocytes in media system A (n=622) were fertilized in
fertilization media A (G-IVF TM PLUS, Vitrolife AB,
Kungsbacka, Sweden) and further cultured in culture media
A (G-1TM PLUS v5, Vitrolife AB, Kungsbacka, Sweden).
Oocytes in media system B (n=584) were fertilised in
fertilization media B (Universal IVF medium, MediCult A/S,
Jyllinge, Danmark) and cultured in culture media B
(EmbryoAssist TM MediCult A/S, Jyllinge, Danmark). When
there were uneven numbers of oocytes, the additional oocyte
was allocated to media system A, which was the standard
system in the clinic at the time of this trial.
Ovarian stimulation and oocyte retrieval
Down-regulation for ovarian hyperstimulation was achieved
by using either a gonadotropin-releasing hormone (GnRH)
agonist or antagonist protocol (Suprecur Hoechst, Frankfurt,
Germany, Synarela, Syntex Nordica AB, Södertälje, Swe-
den; Cetrotide, Serono Laboratories, Aubonne, Switzerland
or Orgalutran, Organon, Oss, the Netherlands), starting on
either cycle day 1 or day 21. Following down-regulation,
ovarian stimulation was induced by using either recombinat
FSH, (Gonal-F, Serono Laboratories, Aubonne, Switzerland,
or Puregon, Organon, Oss, the Netherlands) or urine-derived
Menopur® (Saint-Prex, Switzerland). The starting dose was
dependent on the woman’s age and/or previous response to
ovarian stimulation. The ovarian response was monitored by
means of serum oestradiol assays and vaginal ultrasono-
graphic scans of follicles. Recombinant FSH or Menopur®
was administered until the leading follicle had a diameter
of at least 17 mm. Maturation of the oocyte was triggered
by s.c injection of hCG (Pregnyl, Organon, Oss, the
Netherlands or Ovitrelle, Serono Laboratories, Aubonne,
Switzerland). Oocytes were retrieved by transvaginal
needle aspiration under ultrasonographic guidance 34–
36 h after hCG administration. The cumulus oocyte
complexes were randomly allocated to fertilization medi-
um A or fertilization medium B.
Semen preparation and fertilization
All semen preparation was carried out in Nidacon sperm
preparation media. A two-density gradient (47.5/95%)
(PureSperm® 100, Nidacon International, Mölndal,
Sweden) was used for isolation of motile sperm. Briefly,
liquefied semen was gently overlaid the 47.5% layer and
centrifuged for 15 min at 300×g. The supernatant was
aspirated and 0.5 ml of the pellet was transferred into a
new centrifuge tube and washed twice in 5 ml equili-
brated room-temperature PureSperm® Wash (Nidacon)
for 10 min at 500×g. Sperm concentration was deter-
mined by pipetting an aliquot of 5 μl semen into a
Makler Counting Chamber (Sefi Medical Instruments,
Israel), followed by counting under a phase contrast
microscope.
Conventional IVF was performed in 20 μl fertilization
medium A or fertilization medium B under mineral oil and
about 15,000 spermatozoa were used. The compositions of
the two media used for fertilization is shown in Table 1.
According to lab praxis, insemination was done at about
13.00 and fertilization check in the morning between 07.45
and 09:00 (18–20 h after insemination).
Embryo culture and grading
During the study period, the culture conditions were kept
identical as regards temperature, and pH. The only
difference was the culture media used and protein
supplement. To ensure optimal fertilization and culture
conditions in the incubator, daily manual temperature
readings were performed. The pH of the media was
checked once a week and the CO2 level adjusted for
optimal pH range of 7.2–7.4. Using these criteria, the pH
for both media was within the optimal range (7.2–7.4) as
recommended by the manufacturers.
Following fertilisation after IVF or ICSI, oocytes
were evaluated and cultured in groups of 3–5 under oil
in 20 μl droplets of either culture media A or culture
media B at 37°C in a dual gas incubator (6% CO2 and
94% air). Composition of the two media used for culture
is shown in Table 2. On the morning of day 2 or day 3 the
embryo quality was assessed morphologically on the
basis of the number of blastomeres (cells), the fragmen-
tation rate (volume of embryo with anucleate fragments)
and multinucleation of blastomeres, as described previ-
ously [7, 8]. Each embryo received a score of 0 (top
quality), 1 (good quality), 2 (fair quality) and 3 (poor
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quality). Embryos with a score of 0–2 were used for direct
embryo transfer either on day 2 or day 3, or frozen for
later use by the patient (supernumerary embryos). In this
trial embryos were regarded as of ‘good quality’ when
they were at the 4-cell stage at ~46 h post insemination
(day 2) or at the 8-cell stage, ~ 70 h post insemination
(day 3) and had a score of 0–2. Three embryologists
graded the embryos and together decided on which
embryo had the highest quality. The embryologists
assessing embryo grading and selecting embryos for
transfer or cryopreservation were not blinded as to which
media was used. According to clinic policy one embryo
was transferred in women ≤38 years old and two embryos
in women >38 years old. In cases when embryo quality
was not good, two embryos were transferred regardless of
the woman’s age.
Embryo transfer
Embryo transfers were performed using a soft transfer
catheter (K-JETS-7019-SIVF, Cook, Brisbane, Australia)
under transabdominal ultrasonographic guidance.
Outcome measures
Normal fertilization rate was defined as number of oocytes
containing two pronuclei (2PN) divided by total number of
mature oocytes (MII). Polyploid rate was defined as
number of oocytes containing >2PN divided by total
number of mature oocytes (MII). Embryo quality (EQ)
was defined as number of 4-cell embryos on day 2 and
number of 8-cell embryos on day 3 with a grade of 0–2,
divided by number of normal fertilized embryos. Embryo
G-IVF.v5 Plus
(Vitrolife)
Universal IVF (Medicult) GI.v5 Plus (Vitrolife) EmbryoAssist (Medicult)
Alanyl-Glutamine Water Alanine Water
Calcium chloride
dihydrate
Sodium Chloride Alanyl-glutamine Sodium Bicarbonate
Citrate Human Serum Albumin Asparagine Human Serum Albumin
EDTA Glucose Aspartate Sodium Chloride
Fructose Potassium Chloride Calcium chloride Amino Acids
Gentamicin Calcium Chloride EDTA Hepes Acid
Glucose Sodium Phosphate
monobasic
Gentamicin Calcium Lactate
Glycine Magnesium Sulphate Glucose Potassium Sulphate
Human serum
albumin
Sodium Pyruvate Glutamate Sodium phosphate
L-Alanine Sodium Bicarbonate Glycine Vitamins
L-Asparagine H20 Penicillin Sodium Salt Human serum
albumin
Glucose
L-Aspartate Streptomycine Sulfate Salt Hyaluronan EDTA
L-Glutamate SSR® (Synthetic Serum
Replacement)a
Lipoic acid Sodium Pyruvate
L-Proline Magnesium sulphate Magnesium Sulphate
L-Serine Methionine Penicillin Sodium Salt
Magnesium
sulphate
Potassium chloride Streptomycine Sulfate Salt
heptahydrate Proline SSR® (Synthetic Serum
Replacement)a
Potassium chloride Serine
Sodium chloride Sodium bicarbonate
Sodium dihydrogen Sodium chloride
orthophosphate 1-
hydrate
Sodium citrate
Sodium hydrogen
carbonate
Sodium dihydrogen
phosphate
Sodium lactate Sodium lactate
Sodium pyruvate Sodium pyruvate
Taurine Taurine
Water for injection
(WFI)
Water for injection
(WFI)
Table 1 Composition / Infor-
mation on ingredients of the
fertilization and culture media
a Contains Human Insulin
recombinant.
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utilization rate was defined as the number of embryos
transferred and the number of embryos frozen in relation to
the total number of embryos available. The positive hCG
rate was determined as a ratio between the number of
positive hCG tests and the total number of embryo
transfers. Clinical pregnancy rate was defined as the
number of cases with evidence of at least one gestational
sacs divided by the number of transfers. Implantation rate
was defined as the number of gestational sac/sacs verified
by vaginal ultrasonography divided by the number of
embryos transferred. The Delivery rate was defined as a
ratio between deliveries and embryo transfers.
Statistical analysis
SPSS statistical software (Chicago, Il, USA) was used to
calculate statistics. Power analysis showed that to detect an
increase of 10% in fertilization rate between the two media
systems with a power of 0.8 (alpha-level 0.05), we needed
at least 269 oocytes in each group. Comparison of normal
fertilisation rates, polyploid rates, embryo quality and
embryo utilization rates was performed using the Chi-
square test. Positive hCG rates, clinical pregnancy rates,
implantation rates and delivery rates were compared by
using the Fisher’s exact test (two-tailed). A value of p<0.05
was considered statistically significant.
Results
Normal fertilization rate, polyploid rate, embryo quality
and embryo utilization rate
In total, 1206 oocytes from 110 women were included in
this study. A little over half of them (622; 51.6%) were
fertilized and cultured in media system A (group A) and
584 were fertilized and cultured in media system B (group
B). Patient demographic data including female age, infer-
tility diagnosis and number of oocytes retrieved are given in
Table 2. Regarding the causes of infertility, 7.3% were due
to tubal factor, 7.3% due to endometriosis, 27.3% were
unexplained, 10.9% and 33.6% were due to anovulation
and male factor respectively, and 13.6% due to other factors
This was a sibling-split study and therefore differences in
demographic data were eliminated. The rate of normal
fertilization and the embryo utilization rate were significantly
higher in group A than in group B (73, 5% and 55.5%
compared with 67.2% and 42.9% respectively, p=0.030 and
0.001). There were no differences in polyploidy rate, embryo
quality and the number of embryos cryopreserved between
the groups (Table 3).
Embryo transfer
A total of 108 embryo transfers were performed. Seventeen of
these were mixed transfers, were two embryos, one from each
group were transferred (data not shown). Three embryologists
together agreed on the best quality embryos to be used in
immediate transfer. Additional embryos of high quality were
frozen. A Significantly higher number of transfers were
performed after culture in media system A (75.8%) compared
with system B (24.2%; p<0.0001), as shown in Table 4.
Clinical outcomes
The positive hCG rate, the clinical pregnancy rate, the
implantation rate and the delivery rate were similar in the
two groups (Table 4).
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Table 2 Demographic data of patients included in the study is shown
Patients included (n) 110
Female age, mean±SD (years) 33.9±3.8
Infertility diagnosis, n (%)
Tubal factor 8 (7.3)
Endometriosis 8 (7.3)
Unexplained 30 (27.3)
Anovulation 12 (10.9)
Male factor 37 (33.6)
Other 15 (13.6)
No. of oocytes retrieved per patient, mean±SD 10.9±4.8
Group A Group B P-value
Number of oocytes inseminated, n 622 584 0.122
Mature oocytes (MII), n (%) 520/622 (83.6) 469/584 (80.3) 0.137
Normal fertilized oocytes (2PN), n (%) 382/520 (73.5) 315/469 (67.2) 0.030*
Polyploid (>2PN), n (%) 29/520 (5.6) 34/469 (7.3) 0.282
Embryo quality (grade 0–2), n (%)
with 4-cells at day 2 210/382 (54.9) 163/315 (52.7) 0.396
with 8-cells at day 3 23/382 (6.0) 11/315 (3.5) 0.123
Embryos cryopreserved, n (%) 124/382 (32.5) 111/315 (35.2) 0.439
Embryo utilization, n (%) 212/382 (55.5) 135/315 (42.9) 0.001*
Table 3 Outcome of 1206 sib-
ling oocytes assigned to media
system A or system B.
*Statistically significant
(p<0.05, Chi-square test)
Discussion
In most mammalian species, the intrinsic quality of the
oocyte before it is fertilized determines whether a zygote
has the potential to progress through pregnancy [4]. Human
embryos used for IVF are generally derived from a cohort
of oocytes collected after ovarian stimulation. These
oocytes differ in quality between women and the only
way to study the effect of different media systems is to
compare oocytes from individual women. Therefore, this
study was designed as a sibling-split study, where oocytes
from each woman were divided into two groups and two
different culture systems were used. So far, in previous
studies, randomisation procedures have been performed in
relation to weekdays [9] or other randomisation procedures
have been used [10], increasing the possibility that the
randomisation procedure might influence the final result.
By using sibling oocytes where each patient serves as her
own control, we were able to control for confounding
factors that are inherent to the above mentioned study
designs.
The number of oocytes was higher in group A, which
was a result of the fact that the media system used in this
group was standard in the clinic at the time and when an
uneven number of oocytes was retrieved, the additional
oocyte was allocated to group A.
Detailed composition of the two media is unknown-the
ingredients are to some extent known, as shown in Table 1,
but their concentrations are company secrets. Therefore it is
difficult to determine which ingredients are the most
important for efficient embryo culture. It is noticeable that
the majority of studies carried out to determine the effects
of media additives on embryo development have been
performed using murine or bovine embryos and the
conclusions drawn from these studies might not be valid
for human embryos.
The fertilization rate was significantly higher in group A
than in group B. The fertilization media differ, among other
things, as regards the serum component, sodium citrate,
energy sources, antibiotics, EDTA and taurine. Fertilization
medium A contains human serum albumin and a number of
defined amino acids, while fertilization medium B contains
a synthetic serum replacement component that contains
serum albumin plus other ingredients. It is not known if this
serum replacement component also contains amino acids—
the exact composition is kept secret.
Fertilization medium A contains sodium citrate, which is
not known to be included in fertilization medium B. The
impact of sodium citrate on fertilization is not clearly
understood. It is known that citrate does not seem to
improve sperm motility after freezing [11]. Addition of
citrate to bovine embryo culture appears to enhance morula
and blastocyst development, and hatching [12–14], al-
though in one study no impact on bovine blastocyst
formation was found [15]. The present results indicate that
it could be beneficial for early human embryo development
to have citrate in the fertilization medium.
Energy is needed for fertilization. Fertilization medium
A contains four sources of sugar—fructose, glucose,
pyruvate and lactate—while fertilization medium B con-
tains only glucose and pyruvate. Fructose and glucose are
both energy sources and it has been shown that fructose can
replace glucose, at least as regards bovine embryos [16].
Both lactate and pyruvate are favourable energy sources
for spermatids [17]. For pig embryo development, lactate
and pyruvate for the first 48 h resulted in significantly
higher cell numbers than in those cultured with glucose
only [18]. It was recently shown that lactate increases the in
vitro fertilization rate in mice [19] and this could to some
extent explain why the fertilization rate was higher in group
A. Lactate can not be replaced by pyruvate for energy
requirements, as their mechanisms of action are different.
Pyruvate up-regulates ATP production in sperm and
oocytes, while lactate regulates the redox process instead
of increasing ATP production [20]. Lactate is present in
culture medium B, but this might be too late as regards
optimal early embryo development.
Insulin is used in cell culture systems to promote cell
proliferation [21]. It was recently shown that insulin
enhances sperm motility and the acrosome reaction, as well
as nitric oxide production [22]. Only fertilization medium B
contained insulin, which did not enhanced fertilization rate in
comparison with medium A. However, it is important to
keep in mind that these media are complex and it is difficult
to identify one factor as being more important than any other.
The types of antibiotic used in culture media formula-
tions could be of importance for embryo development.
Follicle bioassay has been found to reveal a concentration-
J Assist Reprod Genet (2011) 28:335–341 339
Group A Group B P-value
Embryo transfer (n) 69 (75.8) 22 (24.2) <0.0001*
Positive hCG, n (% per embryo transfer) 34 (49.3) 11 (50.0) 1.00
Clinical pregnancies, n (% per embryo transfer) 32 (46.4) 8 (36.4) 0.467
Implantation rate, n (%) 36/88 (40.9) 9/24 (37.5) 0.818
Deliveries, n (% per embryo transfer) 24 (34.8) 8 (36.4) 1.000
Table 4 Clinical outcome of 91
embryo transfers, comparing the
two media systems is shown.
*Statistically significant
(p<0.05, Fisher’s exact test
(two-tailed)
dependent decrease in mouse oocyte nuclear maturation
during continuous exposure to streptomycin and a signif-
icantly reduced rate of polar body formation. A lower
fertilization rate was also seen after exposure to streptomy-
cin. Additionally, it has been reported that exposure of
hamster embryos to penicillin and streptomycin reduced the
percentage of 8-cell embryos and blastocysts versus
controls and in comparison with gentamycin alone [23].
This could be one explanation as to why the fertilization
and cleavage rates were lower in media system B,
containing both streptomycin and penicillin.
Chelating agents such as EDTA improve bovine embryo
development [24], but the effect on fertilization is not
known. Only fertilization medium A contains EDTA,
although it is included in both culture media.
Addition of glutamine and hypotaurine has been sug-
gested to improve embryo development by improvement of
intracellular oxidative status [25]. Taurine has also been
shown to improve bovine embryo culture by increasing
total cell number and the rate of blastocyst formation [26].
As far as we know only fertilisation medium B contains
taurine, although it is included in both culture media
Culture medium A contain hyaluronan, which is absent in
culture medium B. Mouse embryos produce hyaluronan, and
its receptor RHAMM is present throughout embryo develop-
ment, suggesting that hyaluronan plays a role at this stage
[27]. Several investigators have shown that hyaluronan-
enriched medium can improve implantation and pregnancy
rates [28–30], but in a recent study we found that although
the implantation rate of human embryos was improved when
adding hyaluronan to the transfer medium, the delivery rate
was not affected, as a result of an increased number of early
pregnancy losses [31].
Embryos cultured in vitro are constantly exposed to
stress factors such as reactive oxygen species (ROS). These
are partly formed during embryo metabolism and are
associated with suboptimal composition of plastics used in
embryo culture. Other sources of ROS are UV light,
volatile organic compounds and oxygen in the air. Culture
medium A contains lipoic acid as an antioxidant. This is a
potent antioxidant which protects embryos in culture [32].
The presence of this acid in culture medium could explain
the superiority of medium A over medium B.
The percentage of embryos transferred was higher after
fertilization and culture in media system A. Three embry-
ologists decided together on the embryos that were of the
highest quality and thereby the best to transfer. The
decision was a professional one with the aim of achieving
the best possible chance of pregnancy for the individual
couple. The embryologists were not blinded to the media in
which the embryos had been cultured. However, the fact
that a higher proportion of embryos cultured in system A
reached the 4 and 8-cell stages is likely to mirror the quality
of the embryos. This is supported by the significantly
higher fertilization and embryo usage rates in group A.
In summary, fertilization medium A contains citrate,
lactate, EDTA and taurine, all favourable for fertilization. In
addition, it contains gentamycin, which is less toxic to
oocytes than streptomycin, which is included in fertilization
medium B. Fertilization medium B on the other hand,
contains insulin, which is thought to be favourable. Taken
together, the combination of nutrients in fertilization
medium A enhances fertilization rate. Culture medium A
is richer and contains hyaluronan, citrate which improves
early embryo development, and a less toxic antibiotic, in
combination with (protective) lipoic acid, which could be
the reason for better early embryo development after culture
in this medium.
In conclusion, the most interesting finding in the present
study is that early embryonic development appears to be
improved, and may even be sped up (ie. more embryos are
at cleaved stage in group A), but since there is no blastocyst
data, chances are that these differences may be minimised
or overcome by day 5 or day 6, and that the outcomes as
relates to implantation and delively are no different (non
randomized outcomes in this study). The data show the
importance of culture media and the fact that increased
effort is needed to improve them further.
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Glycoprotein 130 promotes human
blastocyst development in vitro
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Objective: To investigate the efﬁcacy of leukemia inhibitory factor (LIF) and/or glycoprotein 130 (gp130) on in vitro growth of human
embryos.
Design: Laboratory study.
Setting: University hospital-based IVF clinic.
Patient(s): A total of 164 frozen embryos that survived thawing were cultured in media supplemented with LIF and/or gp130 or control
media.
Intervention(s): Morphological development was evaluated by light microscopy. Protein expression proﬁles of single blastocysts were
evaluated using matrix-assisted laser desorption/ionization time of ﬂight-based intact cell mass spectrometry.
Main Outcome Measure(s): Embryo development and protein content.
Result(s): Addition of gp130 to culture media improved blastocyst formation (73% vs. 43%). Addition of LIF to the culture media did
not improve embryo development. Protein ﬁngerprint spectra were obtained that revealed signiﬁcant intensity changes for multiple
molecular species including thymosin beta-10, thymosin beta-4, histone H2A, histone H2B, histone H4, ubiquitin, ubiquitin-T, and
acyl-CoA binding protein.
Conclusion(s): Glycoprotein 130, but not LIF, seems to be beneﬁcial for preimplantation embryo development, implicating a physio-
logical role in regulating preimplantation development in humans and thus ought to be included in culture media designed for embryo
culture to the blastocyst stage. Furthermore, these ﬁndings highlight the great potential of
matrix-assisted laser desorption/ionization time of ﬂight mass spectrometry and intact cell
mass spectrometry as a versatile tool in reproductive medicine research. (Fertil Steril
2013;99:1592–9. 2013 by American Society for Reproductive Medicine.)
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D espite years of experience andmany technical innovations inassisted reproduction tech-
niques (ART), low implantation rate
is still one of the major obstacles re-
sulting in a large proportion of embry-
onic loss in the ART programs. One
reason might be that a number of em-
bryos fail to develop to the blastocyst
stage probably due to suboptimal
in vitro culture conditions with current
culture media systems. A better under-
standing of basic needs and metabolic
requirements of the early embryo at
different developmental stages is
needed for formulation of new se-
quential culture media, increased
number of embryos reaching the blas-
tocyst stage, and improvement of im-
plantation rates.
Communication between the de-
veloping embryo and the maternal
tract is of importance during the
transport of the early preimplantation
embryo through the fallopian tube. It
is likely that the leukemia inhibitory
factor (LIF) system contributes to this
as it has been shown that LIF and its
receptors are present in the fallopian
tube and in the human preimplanta-
tion embryo (1, 2). Interestingly,
glycoprotein 130 (gp130) is present
in human embryos throughout
embryo development; however, only
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in the inner cell mass (ICM) at the blastocyst stage (2),
suggesting a need for soluble gp130 communication
between the trophectodermal cells of the blastocyst to the
maternal tract at later stages of embryo development, but
not at earlier stages during transport and development in
the fallopian tube. It has previously been shown that
gp130 is needed for embryo development in mice (3), but
the need for gp130 for human embryo development is not
known.
Leukemia inhibitory factor is a cytokine, associated with
reproductive processes such as embryo development and im-
plantation (4). The LIF is an absolute requirement for implan-
tation of murine blastocysts (5, 6). The action of LIF is
mediated through a receptor constellation consisting of LIF
receptor and gp130 subunits (7). The LIF receptor exists in
both soluble and membrane-bound forms with opposite ef-
fects; the soluble form often antagonizes the actions of its li-
gands (8–10). gp130 can also combine with other cytokines,
such as interleukin-6 (IL-6), IL-11, and ciliary neutrophic fac-
tor, to form a high afﬁnity membrane-bound receptor com-
plex (11, 12).
It has been shown that LIF, its receptors, and gp130,
increase in the endometrium at the time of implantation
(4, 7). Women with unexplained infertility have a lower
LIF concentration in uterine ﬂuid and lower protein
expression of LIF receptor and gp130 in the endometrium
compared with fertile women (1, 13–15), suggesting that LIF
and its receptors are important for normal implantation.
Soluble gp130 endometrial secretion is normally increased
during the implantation window, whereas women
with unexplained infertility have decreased secretion of
gp130 (15).
In the present study we evaluated the inﬂuence of LIF and
its receptor gp130 on embryo development using traditional
morphological assessment using light microscopy. In addition
to morphological assessment, protein analysis by matrix-
assisted laser desorption/ionization time of ﬂight mass
spectrometry (MALDI TOF MS) was used for direct protein
proﬁling of intact blastocysts followed by protein identiﬁca-
tion by using bottom-up proteomics and immunoﬂuores-
cence staining.
The aim of the present study was to evaluate the effect of
supplementation with LIF and/or gp130 to the embryo culture
media. Furthermore, protein proﬁling of intact blastocysts by
means of MALDI TOF MS was performed to identify potential
markers of embryo development.
MATERIALS AND METHODS
Ethical Considerations
All embryos used in this study were donated by couples
undergoing IVF treatment at the Centre for Reproduction, Up-
psala University Hospital, Uppsala, Sweden. The embryos
were thawed after 5 years, which according to the Swedish
law is the limit for storage of embryos. After this time it is
not possible to use the embryos for fertility treatment. All
couples gave their written informed consent for the use of
their frozen embryos. The study was approved by the regional
research ethics review board in Uppsala.
Chemicals and Reagents
Ammonium bicarbonate, acetonitrile, 1,4-dithiothreitol (Cle-
land's reagent) (DTT), iodoacetamide, urea, and triﬂuoroacetic
acid were purchased from Sigma Aldrich. Sequence grade
trypsin from bovine pancreas was obtained from Roche. Sina-
pinic acid and protein calibration standard was purchased
from Bruker Daltonics.
Embryo Scoring before Cryopreservation
On the morning of day 2, embryo quality was assessed mor-
phologically on the basis of the number of blastomeres (cells),
the rate of fragmentation (the proportion of the embryo with
anucleate fragments), and the degree of multinucleation of
blastomeres, as described elsewhere (16, 17). Each embryo
received a score of 0 (top quality), 1 (good quality), 2 (fair
quality), or 3 (poor quality). Embryos with a score of 0–2
were used for direct ET, and supernumerary embryos with
scores of 0–1 were cryopreserved for later use. Three
embryologists graded the embryos and together decided on
which embryo(s) to transfer or cryopreserve. The embryo
scoring system is validated twice a year, both internally and
externally according to the International Organization for
Standardization standard.
Freezing of Embryos
Before cryopreservation, embryoswere cultured inmicrodroplets
(G-1 v5 PLUS, Vitrolife AB) overlaid with mineral oil (OVOIL) at
37Cand6%CO2 in ahumidiﬁed incubator. Supernumerary em-
bryoswere cryopreservedonday2 (48hours after ovumpick-up)
according to a controlled rate freezing protocol involving the use
of 1, 2 propanediol and sucrose solution in phosphate-buffered
saline (PBS) as cryoprotectants (Vitrolife AB). This method has
been described elsewhere (18, 19). All embryos used in the
study had been cryostored for at least 5 years.
Thawing of Embryos
The thawing protocol was performed using a commercial kit
according to the instructions from themanufacturer (Thawing
Kit; Cook Medical). The embryos were then transferred into
equilibrated culture medium (CCM; Vitrolife AB). Thawed em-
bryos were then carefully assessed for blastomere survival,
and each embryo received a score of A (100% survival rate),
B (50%% survival rate <100%), or C (<50% survival rate).
Only embryos with a score of A or B were used for the study.
The survived embryos were then randomly allocated, with re-
gard to embryo morphology/survival rate, into four different
treatment regimens and cultured up to blastocyst stage. The
four groups were control, LIF, gp130, or LIFþgp130. The con-
trol embryos were cultured in the standard medium that is
used in the clinic (CCM; Vitrolife AB). For treatment, LIF (Hu-
man Recombinant, 100 ng/mL; Sigma) and/or gp130 (Human
Recombinant, 300 ng/mL; Sigma) was dissolved in standard
medium (CCM; Vitrolife AB).
Embryo Culture
The embryos were cultured individually in 20-mL droplets and
assessed daily for developmental stage. Culture was
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performed at 37C and 6% CO2 in a humidiﬁed incubator.
Each embryo received a score of 0 (top quality), 1 (good qual-
ity), 2 (fair quality), or 3 (poor quality). Fisher's exact test was
used for comparison of results between the different treat-
ment groups.
MALDI TOF MS
Matrix-assisted laser desorption/ionization (MALDI) time of
ﬂight mass spectrometry (TOF MS) is based on direct irradia-
tion with a laser of biological samples previously coated with
an crystalline chemical matrix, which facilitates ionization of
peptides and proteins. The ionized biological molecules are
then analyzed with a time of ﬂight mass analyzer yielding
amass spectrumwhere peptides and proteins can be identiﬁed
based on their molecular weight.
A total of ﬁve blastocysts from each treatment group
(control, gp130, LIF, gp130þLIF) were subjected to individual
MALDI TOF-based intact cell protein analysis. Each blasto-
cyst was analyzed individually using a sandwich target prep-
aration method with sinapinic acid, as described previously
(20). Here, a polished steel target was prespotted with 1 mL
of sinapinic acid matrix solution 1 (1 mg/mL; 100% acetoni-
trile) to give a thin layer of matrix. The individual blastocysts
were washed three times with double distilled H2O under a mi-
croscope and directly applied onto the prespotted MALDI tar-
get plate. A volume of 1 mL sinapinic acid solution II (10 mg/
mL; 50% acetonitrile/0.1% triﬂuoroacetic acid) was spotted
onto the blastocyst thin layer matrix preparation. The samples
were allowed to dry and washed three times with 10 mL of ice
cold 0.1% triﬂuoroacetic acid for salt removal.
All samples were analyzed on an Ultraﬂex II MALDI TOF
mass spectrometer (Bruker Daltonics) equipped with a smart-
beam laser. The mass range of 3–25 kDa was analyzed in
linear positive mode. All spectra were baseline subtracted
(Convex Hull V3), externally calibrated and further processed
by means of peak picking (origin v. 8.1, originlab) and bin-
ning analysis for data reduction (pbin software, available on-
line: www.vicc.org/biostatistics/download/MassSpec/). Bin
integration (area under curve) and total ion current normali-
zation of all raw spectra was performed using an in-house
written script in R. The resulting data were evaluated in Mi-
crosoft Excel (v. 2007) by means of unbiased statistical anal-
ysis using the SAM tool (signiﬁcance analysis of microarrays)
available as macro for Excel (21). Here, nonparametric un-
paired statistical analysis was performed for evaluating
changes between the different sample groups. All SAM results
were followed up by one-way analysis of variance (ANOVA)
and posthoc (Tukey test) analysis (origin v. 8.1).
LC MS-based Protein Identiﬁcation
A total of 30 blastocysts were washed three times in PBS fol-
lowed by freezing/thawing for osmotic membrane disruption
followed by 15 minutes of sonication. The sample was centri-
fuged at 5,000  g and the supernatant collected for immedi-
ate enzymatic protein digestion. A volume of 100 mL of
denaturation buffer (8 M urea, 400 mM ammonium bicarbon-
ate) was added, followed by the addition of 10 mL of DTT (45
mM), and incubation at 55C for 15 minutes for protein
reduction. For alkylation a volume of 10 mL of iodoacetamide
(100 mM) was added followed by incubation at room temper-
ature in darkness. A total of 25 mg of trypsin was reconstituted
in 250 mL of double distilled H2O to give a ﬁnal concentration
of 100 ng/mL. A volume of 20 mL trypsin solution (2 mg, 1:25
wt:wt) was added to the protein solution and incubated at
37C overnight. The samples were desalted on ZipTip C18 col-
umns (Millipore) and dried down in a speedvac system
(Thermo Scientiﬁc).
NanoLC-ESI Fourier transform ion cyclotron resonance
mass spectrometry (FTICR-MS) was performed on an Agilent
1100 nanoﬂow system (Agilent Technologies) hyphenated to
a LTQ-FT 7.0 T (Thermo Scientiﬁc) MS. A volume of 5 mL from
the reconstituted ZipTip fraction was injected automatically
and loaded onto a self-prepared C18 PicoFrit column (75
mm internal diameter/15 mm tip internal diameter; NewObjec-
tive) packed directly inside the electrospray needle tip using
specially designed nanospray emitter tips. A water/formic
acid/acetonitrile solvent system was used where solvent A
was 0.1% formic acid and solvent B was 100% acetonitrile,
0.1% formic acid. Gradient elution was performed in 0 solvent
B for 10 minutes, from 0–50% solvent B for 100 minutes, then
from 50%–90% solvent B for 5 minutes, then in 90% solvent
B for 5minutes, and ﬁnally from 90% back to 0 solvent B for 5
minutes. Peptide elution was followed by ESI FTICR MS and
tandem mass spectrometry (MS/MS) for peptide sequencing
controlled by the Xcalibur software (v.2.0 SR2, Thermo Scien-
tiﬁc). Full-scan spectra were acquired at high resolution
(FWHM ¼ 100,000) using the Fourier transform analyzer.
Data-dependent acquisition was applied for MS/MS precursor
selection, where the ﬁve most intense mass peaks were sub-
jected to subsequent isolation and collision-induced frag-
mentation in the ion trap. Acquired raw data were subjected
to database search against the Uniprot knowledgebase
(www.uniprot.org) using the Mascot software (v. 2.2, Matrix
Science) (22) with the following speciﬁcations: mass toler-
ance (10 ppm; MS/MS, 0.9 Da) enzyme (trypsin), ﬁxed
modiﬁcations (carbamidomethyl), variable modiﬁcations
(oxidation of Met), precursor charge (1þ, 2þ, 3þ) and instru-
ment (ESI-TRAP). Peptide matches with a score above the
conﬁdence threshold (P< .05) were considered to be a signiﬁ-
cant hit. The false-positive identiﬁcation rate was estimated
by searching the data against a decoy database, where the
false-positive identiﬁcation rate threshold was set to <1%.
Embryo Staining
The blastocysts were rapidly transferred from culture and
brieﬂy washed in PBS containing 3 mg/mL polyvinyl pyr-
rolidone and then ﬁxed in 2.5% paraformaldehyde in PBS
for 15 minutes at room temperature. After ﬁxation, the em-
bryos were permeabilized in PBS/polyvinyl-pyrrolidone
buffer containing 0.25% Triton X-100 for 30 minutes. Em-
bryos were then placed in blocking buffer containing 0.1%
bovine serum albumin (BSA) and 0.01% Tween 20 in PBS
for 15 minutes. Primary monoclonal antibody for ubiquitin
(Ubc), histone H4, and thymosin beta-10 (Tyb10; Abcam
Inc.) were diluted in blocking buffer and incubated over-
night at 4C. The embryos were then washed three times
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for 15 minutes each in blocking buffer to remove any un-
bound primary antibodies. The secondary antibody, ﬂuo-
rescein goat anti-rabbit IgG antibody or Texas-red horse
anti-mouse IgG antibody (Vector laboratories), was diluted
in blocking buffer and applied to the blastocysts for 60
minutes at room temperature in the dark. For negative con-
trols, the primary antibody was excluded from the staining
protocol. After incubation, the blastocysts were brieﬂy
washed and mounted on slides in Vectashield with 6-
diamino-2-phenylindole (DAPI; Vector laboratories). The
coverslips were then sealed with nail polish. Stained em-
bryos were viewed by using an inverted microscope (Zeiss
AxioVision, Carl Zeiss Microscopy GmbH) equipped with
ﬂuorescence optics and appropriate ﬁlters.
RESULTS
Embryo Culture
For the present study, a total of 164 embryos survived after
thawing and were cultured for 4r days, which corresponds
to day 6 after insemination. Of these, 73 embryos developed
into blastocysts (44%) and 38 (24%) were of good quality
(i.e., fully expanded or hatching with good quality ICM and
trophectoderm) (Table 1). Culture of embryos in media supple-
mented with gp130 resulted in a signiﬁcantly higher number
of embryos that developed into blastocysts (73%) compared
with controls (37%), LIF (41%), or LIFþgp130 (29%), respec-
tively (Table 1). In addition the number of high quality blas-
tocysts was signiﬁcantly higher in the gp130-treated group
compared with LIFþgp130 (Table 1). Supplementation with
LIF was found not to be beneﬁcial for embryo development.
There was no difference compared with the control group
(Table 1).
MALDI TOF MS
Characteristic protein ﬁngerprint spectra were obtained from
individual blastocysts from the different sample groups
revealing the presence of multiple common protein species
that could be preliminarily assigned according to their accu-
rate mass value. These species included Tyb10, Tyb4, Ubc,
acyl-CoA binding protein (ACBP), 10-kDa heat shock protein,
histones H4, H2A, H2B, and H31, as well as hemoglobin
subunits alpha and beta (Fig. 1). Further identiﬁcation exper-
iments using a LC-MS/MS-based bottom-up proteomic ap-
proach on a large control pool (n ¼ 30) conﬁrmed their
identity based on their signiﬁcant peptide fragmentation
data (P< .05).
Intact cell mass spectrometry revealed characteristic pro-
tein patterns for the different sample groups (Fig. 2). Unbiased
statistics using SAM for unpaired analysis revealed signiﬁ-
cant changes in protein expression between the different
treatment groups (P< .05).
Comparison of gp130-treated blastocysts and controls
showed signiﬁcantly increased peak values for three protein
species. One of the proteins that was increased is probably
ACBP (peak m/z 9968), whereas the other two peaks, m/z
9772 and m/z 19938, were not possible to identify
(Supplemental Fig. 1A, available online). Treatment with
gp130 and LIF in combination resulted in lower protein
levels of Tyb10, histones H2A, H2B, and H4 compared
with controls (Supplemental Fig. 1B). Furthermore, histone
H31 was found decreased in combination with gp30 and
LIF treatment compared with sole treatment with gp130
(Supplemental Fig. 1C).
In contrast no difference between LIF treatment and con-
trol or between LIF and gp130 treatment was observed. A
number of protein peaks were found to be elevated in
LIFþgp130-treated blastocysts compared with sole LIF treat-
ment. On the other hand, only a single unknown protein, m/z
7000.15, was decreased with combination treatment of LIF
TABLE 1
Morphological embryo development assessed by light microscopy.
Treatment
No. of
embryos
Blastocysts
(% of total no.
of embryos)
High quality
blastocysts
(% of total no.
of embryos)
Total 164 73 (44) 40 (24)
Control 43 19 (37)a 10 (23)
gp130 40 29 (73)a,b,c 15 (38)d
LIF 46 19 (41)b 9 (20)
LIFþgp130 35 10 (29)c 6 (17)d
Note: Statistics using Fisher's exact test.
a P¼ .014.
b P¼ .005.
c P¼ .0002.
d P¼ .004.
Hambiliki. gp130 promotes blastocyst development. Fertil Steril 2013.
FIGURE 1
Characteristic protein ﬁngerprint spectra of individual embryos
obtained with matrix-assisted laser desorption/ionization time of
ﬂight mass spectrometry (MALDI TOF MS) analysis. The peaks
represent singly charged individual protein mass peaks that allow
preliminary assignment of the respective protein species based on
the accurate mass value. The protein annotations are based on
their uniprot knowledge base entry (www.uniprot.org).
Hambiliki. gp130 promotes blastocyst development. Fertil Steril 2013.
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and gp130 compared with LIF (Supplemental Fig. 1D). Inter-
estingly, a previously reported C-terminally truncated form
of Ubc1-76 (Ubc-T, Ubc1-74) (23, 24) was found to be
strikingly increased in LIFþgp130 compared with LIF
(Supplemental Fig. 1D, arrow).
Immunohistochemistry
Immunohistochemical staining showed that Ubc is present
both in the ICM and in the trophectoderm of the blasto-
cysts (Fig. 3A). Histone H4 was seen in trophectodermal
cells, whereas no staining appeared to be present in the
ICM (Fig. 3B). Tyb4 was seen in the ICM (Fig. 3C).
Tyb10 was seen mainly in the ICM and trophectoderm
(Fig. 3D).
DISCUSSION
We found a signiﬁcant increase in blastocyst formation after
supplementation of gp130 to the embryo culture media. The
natural environment for development of the human embryo
is at the earlier stages in the lumen of the fallopian tube
and during the later stages in the endometrium of the uterine
cavity. Receptors for LIF and gp130 are present in the fallo-
pian tube and endometrium (1, 2, 25). This is suggestive of
a paracrine interaction between the embryo and the
reproductive tract.
gp130 secretion is elevated in the endometrium at the
time for implantation (15), regulated by the estrogen (E) and
P levels (7). Altered gp130 has previously been associated
with infertility (1, 15). The addition of gp130 to embryo
FIGURE 2
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Matrix-assisted laser desorption/ionization time of ﬂight mass spectrometry (MALDI TOF MS) spectra of single intact blastocysts from different
treatment groups reveal characteristic changes in protein expression proﬁles. Different protein intensities for common species as well as
exclusively present peaks were observed between the treatment groups (arrows). These species served as characteristic identiﬁer masses for the
respective treatment groups.
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culture media increased the number of embryos that
developed to the blastocyst stage. This suggests that gp130
is beneﬁcial for embryo development and could be included
in culture media. One protein that was higher in the gp130
group was ACBP. Mouse homozygous ACBP-null embryos
do not develop beyond the morula stage, whereas wild-type
and heterozygote embryos do, which indicates that ACBP is
of vital importance for embryo development (26). The inﬂu-
ence of LIF seems to be the opposite of gp130 and LIF seem
to be detrimental for embryo development. This is contrary
to the mouse, where LIF enhances blastocyst formation and
birth rates (27). There was no speciﬁc alteration in protein
content that could explain the poor embryo development in
this group. The positive effect of gp130 might be mediated
through the action of other cytokines than LIF, such as IL-6
or IL-11, as gp130 also acts as a receptor for other cytokines
in the IL-6 family, which might have an effect on embryo de-
velopment (11, 12, 28).
To our surprise we found a negative effect of supplemen-
tation with both gp130 and LIF to the culture media. This
might be a dose effect as the blastocyst itself secrets LIF
(29), and that extra supplementation might result in too
high levels of LIF. This could lead to disturbed development
of the embryo, resulting in arrested development. The altered
proteins in this group were Tyb10, histones H2A, H2B, and
H4, and Ubc-T. Ubiquitin has earlier been detected in the se-
cretome of human preimplantation embryos developing into
blastocysts and has been suggested as a marker for good em-
bryo quality (30). Ubiquitin-T, also named Tyb1 or thymosin
polypeptide beta 1, is a small protein found in most tissues of
eukaryotic organisms and is involved in many intracellular
processes such as regulation of protein recycling. The ﬁrst
cell cleavage has been suggested to be regulated by a Ubc
ligase (31). Studies of gene expression of human Ubc-like
modiﬁers show their expression already in the four-cell stage
embryo (32). The Ubc pathway is also important for the devel-
opment of blastocysts in mice (33). Ubiquitin has been
detected in the cytoplasm and the nucleus of trophoblast cells
and has been suggested to be essential for placentation (34).
We found staining for Ubc in both the ICM and trophectoder-
mal cells of human blastocysts, suggesting a function for Ubc
also in the human embryo development. Pre-embryos
cultured with a combination of LIF and gp130 had increased
Ubc-T activity compared with embryos cultured with only LIF
supplementation (Supplemental Fig. 1D). This is somewhat
conﬂicting with the above-mentioned studies as the embryos
FIGURE 3
Immunohistochemical staining of (A) ubiquitin, (B) histone H4, (C) thymosin beta 4, and (D) thymosin beta-10 in human blastocysts. Nuclear staining
with 6-diamino-2-phenylindole (DAPI) is shown in blue.
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cultured with LIFþgp130 were the least developed group.
Growth factor supplementation to culture media is not neces-
sarily an advantage. In a recent study it was demonstrated
that the rate of mosaicism/aneuploidy was higher in mouse
embryos cultured in media supplemented with granulocyte
macrophage colony-stimulating factor (GM-CSF) compared
with controls (35). Tyb10 was reduced in the LIFþgp130
group. Beta-thymosins are small proteins that regulate the
actin cytoskeleton, involved in cell motility and differentia-
tion. Tyb10 is up-regulated in bovine cumulus cells during
in vitro maturation of cumulus-oocyte complexes, positively
correlated with cumulus-oocyte complex expansion and P
secretion and negatively correlated with apoptosis. Tyb10
expression is, however, shown to be unchanged in oocytes
developing to the blastocyst stage compared with arrested
preimplantation embryos (36). During embryogenesis the
control of actin polymerization is essential in processes,
such as cell migration, and is believed to play an important
role in early embryo development in mice (37). Expression
of porcine complementary DNA (cDNA) coding for Tyb10
has also been coupled to embryogenesis in swine (38). The
need for Tyb10 for embryo maturation makes it a possible
marker of embryo development.
Histones undergo post-transcriptional modiﬁcations that
act in diverse biological processes such as gene regulation,
DNA repair, chromosome condensation, and spermatogenesis
(39). The oocyte is rich in histone messenger RNA, which is
needed for replacement of the protamins in sperm nuclei be-
fore fertilization. This accumulated amount of histones is also
needed to meet the needs of the zygote during embryonic ge-
nome activation, which normally occurs at the four- to eight-
cell stage in humans. We found that H3 was up-regulated in
the gp130-treated embryos, with the most favorable embryo
development, compared with the least developed group
treated by LIFþgp130. This might give a clue as to how
gp130 exerts its biological effect on embryo development.
Histone H3 could be a candidate marker, predicting blastocyst
development. We found staining for histone H4 in trophoblast
cells, whereas no staining appeared to be present in the ICM;
therefore histone H4 could be suggested as a marker for tro-
phoblast development. The suggested markers for embryo de-
velopment need to be evaluated in further studies.
Little is known about the protein patterns of early hu-
man embryo development due to small size of the preim-
plantation embryo and the limited number of human
embryos available for research. MALDI TOF MS is a new
powerful technique used to search for both quantitative
and qualitative changes in different biological processes
(40). The development of this proteomic technology has
made it possible to analyze the proteins of single human
preimplantation embryos. The present study shows that the
use of MALDI-TOF MS is a valuable tool for analysis of pro-
tein pattern in early embryo.
In conclusion, we found that supplementation of gp130
to embryo culture media improved the development of human
preimplantation embryos, as seen by the formation of more
blastocysts. The results need to be conﬁrmed in further stud-
ies. Our ﬁndings also highlight the great potential of MALDI
TOF MS as a versatile tool in reproductive medicine research.
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SUPPLEMENTAL FIGURE 1
Statistical investigation of matrix-assisted laser desorption/ionization time of ﬂight mass spectrometry (MALDI TOF MS) data reveals treatment-
speciﬁc protein regulations. Unbiased analysis of protein peak intensities by means of multivariate, unpaired t-statistics was performed using
the signiﬁcance analysis of microarrays (SAM) software. (A) (upper left) Control versus gp130 shows signiﬁcantly lower peak intensities (green)
for three protein mass peaks including m/z 8772, m/z 9968, and m/z 19938. (upper right, lower left to lower right) Manual inspection of the
MS data was performed for veriﬁcation of corresponding protein intensity changes (arrows: black trace ‘‘control’’ vs. red trace ‘‘gp130’’)
observed in SAM analysis. (B) Control versus LIFþgp130. The SAM analysis revealed signiﬁcant changes for many protein peaks (green: lower in
LIFþgp130 and red: higher in LIFþgp130). Here thymosin beta chains 10 (*) and 4 (arrow) as well as histone H4 and histone H2B were found
to be signiﬁcantly decreased in LIFþgp130 compared with controls. (C and D) Combinatory LIFþgp130 supplementation versus gp130 and LIF
treatment, respectively. The SAM analysis revealed signiﬁcant changes for many protein peaks. An up-regulation of histone H3 was observed
for gp130 compared with LIFþgp130 (C). In contrast, a striking increase of ubiquitin-T was observed in LIFþgp130 compared with sole LIF
treatment (D).
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Abstract
Vitrification has become common for cryopreservation of embryos. However, the most optimal protocol for vitrification is still 
to be found. Two vitrification protocols with similar osmolarities were compared: Protocol A, containing dimethyl sulphoxide 
(DMSO), propane-2-diol, and ethylene glycol, and Protocol B, containing propane-2-diol and ethylene glycol. Viability and 
the importance of specific incubation times for early embryo recovery, survival, and cleavage were studied. For assessment of 
cryodamage, embryos were labelled with Alexa Fluor 488-conjugated annexin V and propidium iodide. Vitrification studies on 
early mouse embryos were followed up with studies on human embryos. The two vitrification protocols did not differ in embryo 
survival rates and were equally efficient in both mouse and human embryo models. Morphological assessment of embryos directly 
after vitrification was not a useful tool for assessing survival in this study. Extended exposure of embryos with both vitrification 
protocols showed that the DMSO-containing vitrification solutions did not lead to cell membrane damage and death as quickly 
as the DMSO-free vitrification solutions. To assess embryo viability, the authors recommend that vitrification of early embryos 
should be combined with extended culture and assessment of normal blastocyst development before transferring to patients.
Keywords: cryodamage, cryoloop, fluorescence imaging, post-vitrification survival, vitrification 
Single embryo transfer decreases the risk of multiple pregnancies, 
which may cause preterm birth, low birth weight and perinatal 
death. In addition, single embryo transfer is also the most cost-
effective, when combined with frozen/thawed cycles (Dare et al., 
2004; Pinborg, 2005; Pinborg et al., 2005; Fiddelers et al., 2007). 
Therefore, single embryo transfer is becoming the recommended 
method in an increasing number of countries.
With the reduction in the number of embryos transferred per patient 
during IVF treatment, the need for effective cryopreservation 
methods has increased further. Vitrification has advantages over 
the traditionally used cryopreservation method of slow freezing 
(Rama Raju et al., 2005; Stehlik et al., 2005). Whereas slow 
freezing can cause intracellular ice crystal formation, which 
sometimes causes complete destruction of blastomeres and/or 
whole embryos, vitrification relies on a fast cooling rate that does 
not form ice crystals. Vitrified embryos seem almost unchanged 
morphologically after warming. Vitrification is becoming 
increasingly popular for cryopreserving human gametes and 
embryos (Rama Raju et al., 2005; Takahashi et al., 2005; Selman 
et al., 2006; Antinori, et al., 2007).
One perceived drawback with vitrification is the use of high 
concentrations of cryoprotectants leading to intense dehydration 
and shrinkage of the embryo. Dimethyl sulphoxide (DMSO) is a 
permeating cryoprotectant, which protects cells from intracellular 
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ice crystal formation when used at higher concentrations. This 
characteristic can lead to a higher toxicity compared with a 
cryoprotectant with lower permeation rates. Recent publications 
show that vitrification of human embryos is possible with different 
cryoprotectant solutions, such as DMSO in combination with 
ethylene glycol (EG), or EG alone (Rama Raju et al., 2005; 
Takahashi et al., 2005). The combination of DMSO and EG has 
been used successfully by Desai et al. (2007); however, in some 
IVF clinics employees are hesitant to work with DMSO. This study 
was undertaken to investigate the limits of these cryoprotectants. 
The authors wanted to consider the effects of long-term exposure 
of these cryoprotectants on embryo development. A functional 
protocol works well only if the user performs the protocol properly. 
With vitrification becoming more widespread, there are bound to 
be deviations from the instructions. Commercially available kits 
differ in cryoprotectant components and there is a lack of data 
supporting whether or not to use DMSO-containing or DMSO-free 
vitrification solutions. Using an in-vitro mouse embryo model, the 
objectives were: to compare two vitrification protocols, with and 
without DMSO; to assess viability of vitrified early mouse embryos 
compared with human embryos to recover and develop further into 
expanded blastocysts; to assess cryodamage through fluorescence 
image analysis using markers for cell membrane degeneration.
Materials and methods
Mouse embryo culture
Two-cell mouse embryos (Embryotech Laboratories, Inc, 
Wilmington, MA, USA) were cultured in G-1 v3 (VitroLife 
AB, Kungsbacka, Sweden) in IVF tissue culture dishes (Falcon 
353652, Becton Dickinson, Franklin Lakes, NJ USA) at 37ºC in a 
humidified triple gas incubator (6% CO2, 5% O2, 89% N2). Mouse 
embryos were cultured in groups (at least 5 µl medium/embryo) 
until the blastocyst stage. One to three embryos were vitrified 
at the same time on the cryoloop. After 17 h of culture (day 3), 
mouse embryos (6–8 cell) were cultured in G-2 v3 (VitroLife AB, 
Kungsbacka, Sweden). Blastocyst development was assessed after 
an additional 48 h of culture, day 5. All day 3 early embryos that 
developed into the 6–8-cell stage were used for the study; at least 
50 embryos were used in each group, unless otherwise stated.
Collection and culture of human embryos
The use of human embryos that could not be used for fertility 
treatment was approved by the Ethics Committees of Örebro 
and Uppsala University Hospitals, in Sweden. Written informed 
consent was obtained from all embryo donors and none of the 
donors received any financial reimbursement. The embryos were 
obtained as donations from patients undergoing IVF at the Centre 
of Reproduction, Uppsala University Hospital.
Down-regulation for ovarian stimulation was achieved using a long 
protocol of gonadotrophin-releasing hormone agonist (GnRHa), 
nafarelin (Synarela; Syntex Nordica AB, Södertälje, Sweden), 
administered intra-nasally, starting on either cycle day 1 or 21. 
Following down-regulation, ovarian stimulation was induced 
using recombinant FSH, (rFSH; Gonal-F, Serono laboratories, 
Aubonne, Switzerland or, rFSH; Puregon, NY Organon, Oss, The 
Netherlands). The starting dose was dependent on the patient’s age 
and/or previous response to ovarian stimulation. Ovarian response 
was monitored by serum oestradiol assays and vaginal ultrasound 
scans of follicles. GnRHa and rFSH were administered until the 
leading follicle had a diameter of at least 18 mm. Maturation of 
the oocyte was triggered by one subcutaneous injection of 10,000 
IU of human chorionic gonadotrophin, (HCG; Profasi, Serono 
laboratories, Aubonne, Switzerland). Thirty-seven hours after 
HCG administration, oocytes were retrieved by transvaginal 
needle aspiration under ultrasound guidance.
Conventional IVF was performed in 750 µl medium (G-FERT™ 
PLUS, VitroLife AB, Kungsbacka, Sweden) under mineral oil 
(Ovoil, VitroLife AB, Kungsbacka, Sweden) containing about 
250,000 spermatozoa. For intracytoplasmic sperm injection (ICSI), 
oocytes were stripped of cumulus cells by mechanical pipetting 
after brief exposure to hyaluronidase (HYASETM, VitroLife AB, 
Kungsbacka, Sweden). ICSI was then performed using a Nikon–
Narishige micromanipulation system. Fertilization was evaluated 
18–20 h after insemination. Following fertilization after IVF and 
ICSI, embryos were cultured in groups of three to five under oil in 
20 µl droplets of G-1 v3 Plus. Embryo quality was assessed daily. 
On the morning of day 2 or day 3 the embryo quality was assessed 
morphologically on the basis of the number of blastomeres (cells), 
the rate of fragmentation (the volume of the embryo with anucleate 
fragments) and multinucleation of blastomeres, as described by 
Mohr et al. (1985) and Ziebe et al. (1997). Each embryo received a 
score of 0 (top quality), 1 (good quality), 2 (fair quality) and 3 (poor 
quality). Embryos with a score of 0–2 were used for direct embryo 
transfer either on day 2 or day 3, or frozen for later use by the 
patient (supernumerary embryos). Embryos surplus to treatment, 
all score 3, were not considered to be of acceptable quality for 
transfer, and were donated for the present study.
Materials and methods
Handling media used for embryo collection was G-MOPS PLUS 
(Vitrolife AB, Kungsbacka, Sweden). All media contained human 
serum albumin (HSA), concentration unspecified by manufacturer. 
Propane-2-diol (PrOH), DMSO and EG were all purchased from 
Sigma (St. Louis, MO, USA). Sucrose was purchased from Merck 
(Darmstadt, Germany).
Preparation of vitrification and warming 
solutions
The Protocol A vitrification solution 1 contained 5% PrOH, 5% 
DMSO and 5% EG in handling medium; vitrification solution 2 
contains 10% PrOH, 10% DMSO, 10% EG and 0.5 M sucrose in 
handling medium.
The Protocol B vitrification solution 1 contained 7.5% PrOH and 
7.5% EG in handling medium; vitrification solution 2 contained 
15% PrOH, 15% EG and 0.5 M sucrose in handling medium.
The four warming solutions consisted of 1.0, 0.5, 0.25 and 0 
M sucrose in handling medium. All solutions were prepared in 
advance, sterile filtered, stored at 4ºC and used within 6 weeks.
Experimental preparation for vitrification 
and warming
Solutions (500 µl) were pipetted directly into the corresponding 
wells of a non-toxic 4-well dish (Nunc, Roskilde, Denmark). 379
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Handling media, vitrification solution 1, and vitrification solution 
2 were aliquoted in vitrification wells 1, 2 and 3, respectively. 
In another 4-well dish, warming solutions 1–4 were aliquoted 
into warming wells 1–4. All solutions were equilibrated at room 
temperature in ambient atmosphere.
Vitrification of embryos
The protocol was performed at room temperature and according 
to media manufacturer’s instructions, unless otherwise stated. 
Early mouse and human embryos were rinsed in G-MOPS PLUS, 
transferred to vitrification well 1 for 2 min with a sterile pulled 
glass pipette, then transferred to vitrification well 2 for 45 s. 
One to three embryos were immediately loaded onto a cryoloop 
(Hampton Research, Laguna, CA, USA) and plunged into liquid 
nitrogen and closed in a cryovial submerged in liquid nitrogen.
Warming of embryos
The protocol was performed at room temperature, unless 
otherwise stated. The cryoloop was removed from the vial at low 
temperature and placed directly and quickly into warming well 
1. With a pulled glass pipette, embryos were moved to warming 
well 2 for 2 min, to warming well 3 for another 2 min and then 
transferred to warming well 4 for 2 min. The embryos were further 
cultured in G-2 v3 PLUS until blastocyst stage.
Survival assessment
After 48 h of culture in G-2 v3 PLUS, both mouse and human 
embryos were examined on an inverted microscope (Zeiss 
Axiovert 200, Germany) at ×40 magnification. Survival was 
assessed based on the development to the blastocyst stage and the 
morphological integrity of the inner cell mass and trophectoderm, 
according to the criteria described by Gardner et al. (2000).
Effect of extended exposure to 
cryoprotectants
In order to study the effects of an extended exposure to 
cryoprotectants, mouse embryos were incubated in the last 
vitrification solution for longer periods of time (5, 10, 20 and 30 
min) before loading the cryoloop.
Cryodamage assessment
Apoptosis and necrosis were detected by using the Vybrant 
Apoptosis Assay Kit #2 (Molecular Probes, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. Briefly, 
Alexa Fluor 488-conjugated annexin V was used to mark for 
phosphatidylserine on the plasma membrane’s outer leaflet. In 
conjunction, the embryos were stained with propidium iodide, to 
detect cell membranes that were not intact. Propidium iodide only 
penetrates cells and stains the DNA when the membrane integrity 
is compromised.
Whole embryo staining using immunocytochemistry was also 
used for apoptosis detection and damage to the cytoskeleton. At 
least 10 embryos were used in each group. The embryos were 
fixed with 4% paraformaldehyde, stained with the anti-caspase 
3 or fluorescein isothiocyanate-conjugated–anti-actin or Cy3-
conjugated–anti-tubulin (Sigma-Aldrich Sweden AB, Stockholm, 
Sweden), nuclear stained with bisbenzamide, and mounted on 
glass slides for fluorescence microscopy.
Statistical analysis
Statistical comparisons of adherent cells were performed using the 
chi-squared test (Statistics Package for Social Sciences, Chicago, 
IL, USA) to compare the different groups of vitrified embryos. P 
< 0.05 was considered significant.
Results
The survival rates of mouse and human embryos after vitrification, 
using two different protocols were evaluated. Mouse embryos 
were vitrified at the 6–8-cell stage (n > 50 in each group) whereas 
human embryos were vitrified at day 2 or day 3 in each group (n > 
50 in each group). Using Protocol A, vitrified human embryos had 
a survival rate of 30% (16 of 53) while for Protocol B it was 35% 
(28 of 80). There was no significant difference between the two 
protocols. Human embryos were more sensitive to the vitrification 
procedure than mouse embryos (Table 1).
Figure 1 shows the results of the effect of prolonged exposure 
to cryoprotectants in mouse embryos. These studies showed that 
Protocol A was less detrimental to the mouse embryos than Protocol 
B, when exposed to an extended period of time in vitrification 
solution 2. After 5, 10, 20 and 30 min in vitrification solution 2, 
the survival rate using Protocol A was 81, 84, 47, 0% (n = 44/54, 
43/51, 24/51, 0/41) while for Protocol B it was 77, 67, 27, 2.5% 
(n = 43/56, 34/52, 15/55, 1/40). There was a significant difference 
between the survival rates for Protocol A and Protocol B when 
subjecting the mouse embryos to 10 and 20 min in vitrification 
solution 2 (P ≤ 0.05). There was a significant decrease in survival 
rates after 20 min in vitrification solution 2 compared with the 
control mouse embryos (P ≤ 0.001).
Some of the vitrified early embryos, even after prolonged 
exposure to the highest concentration of cryoprotectants, seemed 
almost unchanged morphologically after warming, but after 48 h 
in culture, the viability of the embryos was dramatically reduced. 
Despite the excellent morphology seen in most embryos exposed 
for 30 min to either vitrification solution 2, the embryos failed to 
develop further (Figure 2).
Whereas both protocols preserved the visible integrity of 
the plasma membrane even after excessive exposure to 
cryoprotectants, fluorescence staining showed that cell death was 
linked to membrane damage. Mouse and human embryos that were 
vitrified according to the protocol incubation times (the shortest 
recommended by the media manufacturer) showed no annexin 
V staining. Embryos exposed to longer incubation in vitrification 
solution 2 showed blastomeres with signs of membrane damage 
(Figure 3). The morphology in Figure 3 depicts fixed embryos, 
which have fewer spherical blastomeres than seen during culture. 
Labelling with anti-caspase-3 (Figure 4), a common marker for 
apoptosis, showed that the previous annexin V staining was due 
to apoptosis in mouse embryos. There were no differences in the 
structures of the cytoskeletal proteins, actin and tubulin, after 
vitrification with either protocol.380
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Table 1: Comparison of Protocols A (with dimethyl sulphoxide;  
DMSO) and B (without DMSO) in mouse and human model systems. 
 Survival (%, number survived/total number)
 Mouse embryos Human embryos
Control  83 (45/54) 32 (16/50)
Protocol A  77 (43/56) 30 (16/53)
Protocol B  80 (45/56) 35 (28/80)
There were no statistically significant differences in embryo survival compared with the  
control (non-vitrified) group. Survival was defined as development to the blastocyst  
stage in vitro.
Figure 1. There was a significant difference between 
the survival rates of Protocol A, containing dimethyl 
sulphoxide (DMSO), propane-2-diol and ethylene glycol, 
and Protocol B, containing propane-2-diol and ethylene 
glycol, compared with the control (non-vitrified) mouse 
embryos when subjecting the mouse embryos to 10 and 
20 min in vitrification solution 2, *P ≤ 0.05. There was 
a significant decrease in survival rates after 20 min in 
vitrification solution 2 compared with the control mouse 
embryos, ***P ≤ 0.001 (chi-squared test).
Figure 2. Embryo morphology seen directly after warming of a vitrified mouse embryo (a) using Protocol A according to the 
established protocol; after 48 h in culture, development to a blastocyst (b). A vitrified mouse embryo using Protocol A, exposed for 
30 min in vitrification solution 2, after warming (c) ceased to develop further (d). The scale bar in panel (d) applies to all panels.
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Figure 3. Staining of a control (non-vitrified) mouse embryo (a), a vitrified mouse embryo according to the established Protocol 
A (b) and mouse embryos exposed to vitrification solution 2 for 20 min (c) or 30 min (d) with Protocol A compared to the control 
(non-vitrified) mouse embryos. Green staining shows annexin V binding (early apoptosis) and red staining with propidium iodide 
shows necrotic cells (broken cell membranes).
Figure 4. Immunostaining with anti-caspase-3 (red) of a control (non-vitrified) mouse embryo (a), a vitrified mouse embryo 
according to the established Protocol A (b) and a mouse embryo exposed to vitrification solution 2 for 30 min according to Protocol 
A (c) compared with the control (non-vitrified) mouse embryos. The blue stain is bisbenzamide, which stains all nuclei. The scale 
bar in panel (c) applies to all panels.
Discussion
The pregnancy rate is still considerably less after transfer of 
frozen embryos compared with fresh embryo transfer (Oktay 
et al., 2006). This could only be partially explained by the fact 
that the highest quality embryos are used for fresh transfers. 
Therefore, it is essential that new and better vitrification 
techniques for embryos are developed.
Most of the successful vitrification methods published involve 
vitrification solutions that include DMSO and EG in combination 
at concentrations of up to 15% for each cryoprotectant (Matsui et 
al., 1995; Selman et al., 2006; Desai et al., 2007). To minimize, 
but not completely abolish DMSO, Protocol A was created using 
DMSO, EG and PrOH. This allowed a reduced amount of each 
cryoprotectant; that is, 5% (vitrification solution 1) then 10% 
(vitrification solution 2) of each cryoprotectant. To compare this 
‘low-DMSO’ protocol with a DMSO-free formulation, Protocol 
B contained EG and PrOH at 7.5% (vitrification solution 1) and 
then 15% (vitrification solution 2) of each cryoprotectant. Both 
protocols worked well, both for mouse and human embryos, 
when following the established procedure of 2 min exposure in 
vitrification solution 1 and 45 s in vitrification solution 2.
The effect of extended exposure to cryoprotectants on embryo 
survival was used to compare Protocol A and Protocol B. 
The DMSO-containing solutions used in Protocol A, were 
significantly less detrimental to mouse embryos after 10 and 
20 min in vitrification solution 2, compared with the DMSO-
free Protocol B (both P ≤ 0.05). Low salt concentration has 
been used for the cryopreservation of oocytes, with acceptable 
pregnancy rates after frozen egg–embryo transfer (Boldt et 
al., 2006). In the present study, the overall osmolarity for both 
protocols was similar so the differences in results could be due to 
the addition of PrOH and/or the decreased concentration of the 
individual cryoprotectants, namely DMSO and EG from 15% 
concentration to 10%. There are concerns regarding PrOH as a 
cryoprotectant because it has shown cytotoxicity (Fahy, 2007). 
However, the likelihood that the decrease in survival rates is due 
to the addition of PrOH is unlikely as the concentration of PrOH 
was only 10% and it has been reported that toxicity increased in 
PrOH-based vitrification solutions as the concentration increased 
from 30 to 40%. (Mukaida et al., 1998). Cryoprotectants can be 
transported through the cell membrane by aquaporins (Edashige 
et al., 2003; Yamaji et al., 2006). EG diffuses into and leaves the 
embryos very rapidly owing to its low molecular weight, hence 
embryos may undergo less osmotic stress during vitrification 
and warming. Intracellular ice is more likely to form when the 
permeation of the cryoprotectants and its concentration in the 
cytoplasm are insufficient. DMSO is relatively polar and has a 
small and compact structure, which allows it to penetrate living 
tissues rapidly without causing significant damage.
When working with the vitrification protocol, the incubation time 
for the critical final step is 45 s. This step can take longer if the 
user is not comfortable or experienced with loading the embryos 
on the cryopreservation vehicle; thus leading to a prolonged time 
in the vitrification solution with the highest concentrations of 
cryoprotectants. Thus prolonged exposure of embryos during the 
final step was investigated.
The investigation of extended exposure to vitrification solution 
2 was only performed on mouse embryos as the number of 
human embryos was limited. However, it is likely that the same 
mechanisms are involved in the cryodamage of both mouse and 
human embryos. Although embryos were subjected to extended 
exposure to the last vitrification solution, the blastomeres did 
not seem to be damaged upon warming. Continued culture 
to the blastocyst stage, however, showed otherwise. Whereas 
both protocols preserved the visible integrity of the plasma 
membrane even after excessive exposure to cryoprotectants, 
fluorescence staining showed that the blastomeres did not have 
intact cell membranes as propidium iodide could penetrate 
through the cell membrane and stain the DNA.
Furthermore, phosphatidyserine was shown to be on the wrong 
(the outer) leaflet of the cell membrane. This phospholipid 
asymmetry could have been a result of membrane damage due 
to the vitrification and warming process and/or apoptosis. To 
investigate apoptosis further, embryos were immunostained 
with anti-caspase-3. Extended exposure to high concentrations 
of cryoprotectants led to membrane damage characteristic of 
apoptosis and necrosis. These studies were performed only in 
mouse embryos, assuming that the same mechanism also occurs 
in human embryos.
The low survival rate of the human embryos used in this study 
could be due to the extended culture and definition of survival 
used. Survival, in this study, was defined as the percentage of 
embryos that continued to develop to the blastocyst stage in 
vitro. This extended culture was necessary as morphological 
assessment was not sufficient.
Vitrification of day-2 or -3 cleavage-stage embryos instead of 
day-5 blastocysts has several advantages. Since morphology 
alone of a vitrified and warmed embryo is not enough to assess 
viability, the possibility of culturing for a few more days 
before transfer can ensure that a viable embryo will be used 
for transfer. This is also advantageous as it was observed that 
embryo transfer at day 5, in comparison to day 2 or 3, gives 
an increased pregnancy and implantation rate (Graham et al., 
2000; Milki et al., 2000). The reason behind this, besides natural 
embryo selection, may be improved embryo–uterine synchrony 
and decreased cervical mucus (Milki et al., 2000). Another 
benefit to day-2 or -3 vitrification is that there is no need for 
artificial shrinkage at the early cleavage-stage, whereas at day 
5 it is necessary to puncture the blastocoele to avoid formation 
of ice crystals during vitrification (Vanderzwalmen et al., 2002; 
Hiraoka et al., 2004; Mukaida et al., 2006).
Based on the conclusions drawn from this study, it is obvious 
that morphological assessment of vitrified embryos directly 
after warming can be misleading. Blastomeres are almost 
always fully expanded and there is no morphological sign of 
cellular damage. Both mouse and human embryos vitrified 
accordingly showed very little cryodamage upon warming (less 
than 5%), which is comparable to other reports (Desai et al., 
2007). The fully expanded blastomeres can be a result of water 
diffusion through the cell membrane to maintain an iso-osmolar 
equlibrium.
Cryodamage due to vitrification can occur when the concentration 
of cryoprotectant is insufficient inside the cytoplasm (low 
concentration or low exposure or low permeation), leading to 
crystallization or when osmotic changes are too drastic (Storey, 
1997). This is seen when the warmed embryo has a glass-like 383
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morphology, as if the embryo was fixed. The damage is then 
physical and morphologically apparent. However, embryo 
survival cannot be evaluated solely on a morphological basis. 
The authors have shown that despite good morphology upon 
warming, developmental ability is compromised if the embryo 
has been exposed to cryoprotectants for too long. These 
embryos re-expand to their original volume upon warming but 
are not viable.
This study investigated the chemical injury associated 
with vitrification. The authors have shown that the DMSO-
containing vitrification solution leads to less chemical injury 
upon prolonged exposure compared with the DMSO-free 
vitrification solution, possibly due to the fast penetrating 
characteristics of DMSO. DMSO can penetrate the cytoplasm 
quickly, thus stabilizing the osmolarity in the cells to correspond 
to the extracellular osmolarity.
In conclusion, the two standard vitrification protocols, DMSO-
containing and DMSO-free, did not differ in embryo survival 
rates and were equally efficient in both mouse and human 
embryo models. Morphological assessment of embryos 
directly after vitrification is not a reliable tool for assessing 
survival. Extended exposure to vitrification solutions using 
both vitrification protocols showed that the DMSO-containing 
vitrification solutions were milder and did not lead to cell 
membrane damage and death as quickly as the DMSO-free 
vitrification solutions. Since it is not possible to use molecular 
markers on whole embryos to be used clinically, vitrification of 
early embryos may be combined with extended culture to the 
blastocyst stage with assessment of normal embryo development 
before transferring to patients.
References
Antinori M, Licata E, Dani G et al. 2007 Cryotop vitrification of 
human oocytes results in high survival rate and healthy deliveries. 
Reproductive BioMedicine Online 14, 72–79.
Boldt J, Tidswell N, Sayers A et al. 2006 Human oocyte 
cryopreservation: 5-year experience with a sodium-depleted slow 
freezing method. Reproductive BioMedicine Online 13, 96–100.
Dare MR Crowther CA, Dodd JM et al. 2004 Single or multiple 
embryo transfer following in vitro fertilisation for improved 
neonatal outcome: a systematic review of the literature. Australian 
New Zealand Journal of Obstetrics and Gynaecology 44, 283–291.
Desai N, Blackmon H, Szeptycki J et al. 2007 Cryoloop vitrification 
of human day 3 cleavage-stage embryos: post-vitrification 
development, pregnancy outcomes and live births. Reproductive 
BioMedicine Online 14, 208–213.
Edashige K, Yamaji Y, Kleinhans FW et al. 2003 Artificial expression 
of aquaporin-3 improves the survival of mouse oocytes after 
cryopreservation. Biology of Reproduction 68, 87–94.
Fahy GM 2007 Theoretical considerations for oocyte cryopreservation 
by freezing. Reproductive BioMedicine Online 14, 709–714.
Fiddelers AA, Severens JL, Dirkens CD et al. 2007 Economic 
evaluations of single- versus double-embryo transfer in IVF. 
Human Reproduction Update 13, 5–13.
Gardner DK, Lane M, Stevens J et al. 2000 Blastocyst score affects 
implantation and pregnancy outcome: towards a single blastocyst 
transfer. Fertility and Sterility 73, 1155–1158.
Graham J, Han T, Porter R et al. 2000 Day 3 morphology is a poor 
predictor of blastocyst quality in extended culture. Fertility and 
Sterility 74, 495–497.
Hiraoka K, Hiraoka K, Kinutani M et al. 2004 Blastocoele collapse 
by micropipetting prior to vitrification gives excellent survival and 
pregnancy outcomes for human day 5 and 6 expanded blastocysts. 
Human Reproduction 19, 2884–2888.
Matsui M, Takahashi Y, Hishinuma M et al. 1995 Insulin and insulin-
like growth factor-I (IGF-I) stimulate the development of bovine 
embryos fertilized in vitro. Journal of Veterinary Medical Science 
57, 1109–1111.
Milki AA, Hinckley MD, Fisch JD et al. 2000 Comparison of 
blastocyst transfer with day 3 embryo transfer in similar patient 
populations. Fertility and Sterility 73, 126–129.
Mohr LR, Trounson A, Freeman L et al. 1985 Deep-freezing and 
transfer of human embryos. Journal of In Vitro Fertilization and 
Embryo Transfer 2, 1–10.
Mukaida T, Oka C, Goto T et al. 2006 Artificial shrinkage of 
blastocoeles using either a micro-needle or a laser pulse prior 
to the cooling steps of vitrification improves survival rate and 
pregnancy outcome of vitrified human blastocysts. Human 
Reproduction 21, 3246–3252.
Mukaida T, Wada S, Takahashi K et al. 1998 Vitrification of human 
embryos based on the assessment of suitable conditions for 8-cell 
mouse embryos. Human Reproduction 13, 2874–2879.
Oktay K, Cil AP, Bang H 2006 Efficiency of oocyte cryopreservation: 
a meta-analysis. Fertility and Sterility 86, 70–80.
Pinborg A 2005 IVF/ICSI twin pregnancies: risks and prevention. 
Human Reproduction Update 11, 575–593.
Pinborg A, Lidegaard O, la Cour Freisleben N et al. 2005 
Consequences of vanishing twins in IVF/ICSI pregnancies. Human 
Reproduction 20, 2821–2829.
Rama Raju GA, Haranath GB, Krishna KM et al. 2005 Vitrification 
of human 8-cell embryos, a modified protocol for better pregnancy 
rates. Reproductive BioMedicine Online 11, 434–437.
Selman H, Angelini A, Barnocchi N et al. 2006 Ongoing pregnancies 
after vitrification of human oocytes using a combined solution of 
ethylene glycol and dimethyl sulfoxide. Fertility and Sterility 86, 
997–1000.
Stehlik E, Stehlik J, Katayama KP et al. 2005 Vitrification 
demonstrates significant improvement versus slow freezing of 
human blastocysts. Reproductive BioMedicine Online 11, 53–57.
Storey KB 1997 Organic solutes in freezing tolerance. Comparative 
Biochemistry and Physiology Part A 117, 319–326.
Takahashi K, Mukaida T, Goto T et al. 2005 Perinatal outcome of 
blastocyst transfer with vitrification using cryoloop: a 4-year 
follow-up study. Fertility and Sterility 84, 88–92.
Vanderzwalmen P, Bertin G, Debauche C et al. 2002 Births after 
vitrification at morula and blastocyst stages: effect of artificial 
reduction of the blastocoelic cavity before vitrification. Human 
Reproduction 17, 744–751.
Yamaji Y, Valdez DM Jr, Seki S et al. 2006 Cryoprotectant 
permeability of aquaporin-3 expressed in Xenopus oocytes. 
Cryobiology 53, 258–267.
Ziebe S, Petersen K, Lindenberg S et al. 1997 Embryo morphology 
or cleavage stage: how to select the best embryos for transfer after 
in-vitro fertilization. Human Reproduction 12, 1545–1549.
Declaration: The authors report no financial or commercial 
conflicts of interest.
Received 4 October 2007; refereed 31 October 2007; accepted 12 
March 2008.
384
RBMOnline®



STEM CELL BIOLOGY
Co-localization of NANOG and OCT4 in human
pre-implantation embryos and in human embryonic stem cells
Fredwell Hambiliki & Susanne Ström & Pu Zhang &
Anneli Stavreus-Evers
Received: 14 March 2012 /Accepted: 14 June 2012 /Published online: 29 June 2012
# Springer Science+Business Media, LLC 2012
Abstract
Purpose NANOG and OCT4 are required for the mainte-
nance of pluripotency in embryonic stem cells (ESCs).
These proteins are also expressed in the inner cell mass
(ICM) of the mouse pre-implantation embryo.
Methods Immunohistochemistry was used to show the pres-
ence of NANOG and OCT4 protein, and in situ hybridization
was used to localize NANOGmRNA in human embryos from
two-cell to blastocyst stage, and in human ESCs (hESCs).
Results Nanog and Oct4 were co-localized in human em-
bryos from morula and blastocyst stages. NANOG mRNA
was detected in a group of cells in the morula, in cells of the
ICM of blastocysts, and evenly in hESCs. All non-
differentiated hESCs expressed NANOG and OCT4 protein.
Pluripotent cells expressing NANOG and Oct4 were eccen-
trically localized, probably in polarized cells in a human
compacted morula, which appears to be different from ex-
pression in murine embryos.
Conclusion In this study, we demonstrate that whole mount
in situ hybridization is amenable to localization of mRNAs
in human development, as in other species.
Keywords Pluripotency . Embryo . Embryonic stem cells .
NANOG . In situ hybridization
Introduction
Embryo development seems to be tightly regulated during
each developmental stage, although the exact mechanisms
are not completely understood. The transition from morula
to blastocyst involves segregation of the first two cell line-
ages in the pre-implantation embryo, the inner cell mass
(ICM), which forms the embryo, and the trophectoderm,
which gives rise to the trophoblast lineage. Two transcrip-
tion factors, OCT4 and NANOG, are the two most studied
factors concerning formation of the ICM in mouse embryos,
and it has been shown that these two intrinsic factors are
required for establishment of the ICM in an undifferentiated
state [3, 18, 20]. OCT4 and NANOG are expressed in
human pre-implantation embryos and human embryonic
stem cells (hESCs) and these transcription factors regulate
stem cell pluripotency and differentiation [6, 15, 28]. The
OCT4 gene is a member of the mammalian POU family of
transcription factor genes. OCT4 is expressed in both ESCs
and embryonic carcinoma cells [22, 26, 27, 33] and is
considered to be essential for pluripotency [20, 21]. Dele-
tion of the OCT4 gene allows blastocyst formation but
failure as regards pluripotency, which results in differentia-
tion into a trophectodermal lineage [20]. OCT4 is expressed
constitutively throughout the pre-implantation period [15].
NANOG is a more recently described homeodomain-
bearing protein. It acts as a transcription factor and has been
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described in mouse pluripotent cells [3, 18]. NANOG is
expressed in a restricted number of cell types, and only in
cells that also express OCT4, including ESCs [4]. In the
mouse embryo, NANOG is localized in the centre of the
morula and in the ICM of the blastocyst [3]. NANOG-
induced self-renewal and NANOG function, but not
NANOG expression, are dependent on continued OCT4
expression. OCT4 is required for NANOG-induced self-
renewal [3, 17, 18]. Genetic deletion of NANOG in mouse
ESCs resulted in the production of primitive endoderm-like
cells, and NANOG mutant embryos were able to produce
parietal endoderm. Since embryos lacking Oct4 are unable
to develop so far this resulted in the assumption that
NANOG function is critical during a later developmental
stage than is the case for OCT4 [3, 18], and NANOG has
been shown to be expressed from the 4-cell stage onwards
[15]. Following implantation, when the ICM is developing
into epiblast and primitive endoderm, NANOG is expressed
in the epiblast cells [8].
The ability to visualize the expression of a gene in both
time and space in human pre-embryos would be an essential
tool in developmental biology. Whole-mount in situ hybrid-
ization has the advantage of showing the cellular location of
specific mRNAs. However, to our knowledge, the method
has not been used for studies on mRNA expression in
human pre-embryos. Therefore, the aim of the present study
was to optimise and use a novel whole-mount in situ hy-
bridization method to determine the mRNA expression of
NANOG in human embryos.
Materials and methods
Ovarian stimulation and in vitro fertilization
Down-regulation for ovarian hyperstimulation was achieved
by using a long protocol gonadotrophin-releasing hormone
agonist (GnRHa), nafarelin (Synarela; Syntex Nordica AB,
Södertälje, Sweden) administered intra-nasally, starting on
either cycle day 1 or 21. Following down-regulation, ovar-
ian stimulation was induced using recombinant FSH (rFSH;
Gonal-F, Serono Laboratories, Aubonne, Switzerland, or
Puregon, NY Organon, Oss, the Netherlands). The starting
dose was dependent on the subject’s age and/or previous
response to ovarian stimulation. Ovarian response was mon-
itored by serum estradiol assays and vaginal ultrasound
scans. GnRHa and rFSH were administered until the leading
follicle had a diameter of at least 18 mm. Maturation of the
oocyte was triggered by one s.c. injection of 10,000 IU of
human chorionic gonadotrophin (hCG; Profasi, Serono lab-
oratories, Aubonne, Switzerland). Thirty-seven hours after
hCG administration, oocytes were retrieved by trans-vaginal
needle aspiration under ultrasonographic guidance.
Conventional IVF was performed in 20-μl droplets of
medium (IVF medium, Vitrolife AB, Gothenburg, Sweden)
containing about 15,000 spermatozoa, under oil (Ovoil,
Vitrolife AB, Gothenburg, Sweden).
For intracytoplasmic sperm injection (ICSI), oocytes were
stripped of cumulus cells by mechanical pipetting after brief
exposure to hyaluronidase (HYAS; Vitrolife AB, Gothenburg,
Sweden). ICSI was then performed using a Nikon-Narishige
micromanipulation system. Fertilization was evaluated 18–
20 h after insemination. Following fertilization, IVF and ICSI
embryos were cultured in 10-μl droplets of medium under oil
(G.1.2; Vitrolife AB, Gothenburg, Sweden).
Embryo transfer was carried out either on day 2 or day 3.
Excess embryos, surplus to treatment, were frozen at the 2-
to 8-cell stage using a three-stage propanediol cryopreser-
vation kit (Freeze kit 1; Vitrolife AB, Gothenburg, Sweden)
according to the manufacturer’s instructions. Embryos used
for immunohistochemistry, n031, and in situ hybridization,
n089, were cyopreserved and thawed after their 5-year
storage limit in liquid nitrogen had passed. Frozen embryos
were thawed using a thawing kit (Sydney IVF thawing kit,
CooK IVF, Brisbane, Australia), and cultured to blastocysts
in 10-μl droplets under oil in either BlastAssist System
(Medicult, Jyllinge, Denmark) or blastocyst (Sidney IVF
Blastocyst medium, CooK IVF, Brisbane, Australia) se-
quential media.
Human embryonic stem cell derivation and culture
The embryos used for embryonic stem cell culture had been
donated on day 2 after fertilization after all embryos of good
quality (minimum score of 2.0 out of 3.5 according to [19])
had been transferred or frozen. From an original score of
3.5, reductions of 0.5 at a time were made on the basis of the
following features: more than 20 % cellular fragmentation,
unequal size of blastomeres, multinuclear blastomeres, or
the embryo did not fill the zona.
The blastocysts used for the present embryonic stem cell
lines had been cultured in medium designed for blastocyst
culture (MediCult, Ronnehavn, Denmark). Derivation of the
present lines was carried out as described previously [13,
14]. Separation of the ICM from the trophectoderm cells
was carried out by first removing the zona pellucida, using
0.5 % pronase (Sigma-Aldrich, Stockholm, Sweden). The
trophectoderm was removed by immunosurgery as described
earlier, using rabbit antihuman whole serum (Sigma) and
guinea pig complement serum (Sigma-Aldrich, Stockholm,
Sweden) [30]. The isolated ICMswere then placed on a feeder
cell layer.
Human foreskin fibroblasts (CRL-2429; ATCC, Mana-
ssas, VA) were used as feeder cells. The feeder cells were
mitotically inactivated using irradiation (35 Gy) and plated
onto 2.84-cm2 dishes to form a confluent monolayer to be
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used as substrate cells the following day. 150,000 fibroblasts
were plated for derivation of a new line, and for the passages
to follow, 350,000 fibroblasts were plated. Iscove’s medium
(Gibco, Invitrogen, Stockholm, Sweden) supplemented
(10 %) with FCS (Gibco, Invitrogen, Stockholm, Sweden)
was used as culture medium.
The culture medium used for derivation and culture of
hESCs consisted of Dulbecco’s modified Eagle’s medium
(Gibco, Invitrogen, Stockholm, Sweden) supplemented
(20 %) with SR medium (Knockout SR, Gibco, Invitrogen,
Stockholm, Sweden), 2 mM L-glutamine (Gibco, Invitrogen,
Stockholm, Sweden), 1 % penicillin-streptomycin (Gibco
Invitrogen Corporation), 1 % nonessential amino acids
(Gibco, Invitrogen, Stockholm, Sweden), 0.5 mM 2-
mercaptoethanol, 1 % insulin-selenium-transferrin (Sigma-
Aldrich, Stockholm, Sweden) and bFGF (8 ng/ml; R&H
Systems, Oxon, U.K.).
After an initial growth period of 12 days, the cell aggre-
gates were removed mechanically from the original plate
and transferred to fresh feeder cells. Mechanical passage
was performed by cutting the colony (approximately
2,000 μm in diameter) into eight pieces using a scalpel,
under a stereomicroscope. Mechanical splitting was then
carried out at 5- to 8-day intervals (mean, 7 days). Non-
differentiated cells, as judged by morphology, were chosen
for each further passage. The doubling time of the hESCs
was approximately 24 h. In vivo pluripotency was tested in
embryonic bodies and teratomas. The lines used in this
study were HS181, HS235 and HS237. For cryopreserva-
tion of the cells, vitrification in pulled open straws, using
ethylene glycol, dimethylsulphoxide (20 % each) and 1 M
sucrose as cryoprotectants.
In situ hybridization of NANOG in human preimplantation
embryos
A non-radioactive whole mount in situ hybridization meth-
od was used to detect the presence of NANOG mRNA in
human preimplantation embryos. The experiment was per-
formed on batches of ten or more embryos. The embryos
were placed in culture inserts, which were thereafter trans-
ferred into wells that contained the different solutions. In the
first step the embryos were washed twice in phosphate-
buffered saline (PBS), and then fixed overnight at 4 °C in
4 % paraformaldehyde. After fixation the embryos were
washed twice in PBS with 0.1 % Tween-20 (Sigma-Aldrich,
Stockholm, Sweden) (PBT). Dehydration was performed
through increasing concentrations of methanol in PBS
(25 %, 50 %, 75 %) and finally twice in 100 % methanol.
Rehydration was carried out through decreasing concentra-
tions of methanol/PBS (75 %, 50 %, 25 %). The embryos
were then rinsed three times with PBT followed by three
washes in a detergent mix of 150 mM NaCl (Sigma-Aldrich,
Stockholm, Sweden), 1 % Nonidet-P-40 (Sigma-Aldrich,
Stockholm, Sweden), 0.5 % sodium deoxycholate (Sigma-
Aldrich, Stockholm, Sweden), 0.1 % SDS (Sigma-Aldrich,
Stockholm, Sweden), 1 mM EDTA (Sigma-Aldrich, Stock-
holm, Sweden) and 50 mM Tris (Sigma-Aldrich, Stock-
holm, Sweden), pH 8.0, at room temperature. Post-fixation
was carried out in 4 % paraformaldehyde (Sigma-Aldrich,
Stockholm, Sweden), 0.2 % EM-grade glutaraldehyde (Sig-
ma-Aldrich, Stockholm, Sweden) in PBT at room tempera-
ture. Thereafter, the embryos were washed in PBT followed
by a wash in a 1:1 mix of hybridization buffer (HB; 50 %
ultra-pure formamide (Sigma-Aldrich, Stockholm, Sweden),
5 × SSC pH 4.5, heparin at 50 μg/ml, 0.1 % Tween 20) and
PBT at room temperature. Prehybridization was then per-
formed for 3 h at 70 °C in HB containing tRNA (100 μg/ml)
and sheared denatured herring sperm DNA (Sigma-Aldrich,
Stockholm, Sweden) at 100 μg/ml, followed by hybridiza-
tion overnight at 70 °C in HB containing tRNA (100 μg/ml)
and denatured digoxigenin-labelled riboprobe (100 μg/ml).
Human NANOG ORF was subcloned from IMAGE clone
664153 using ATC TCG AGG CCG CCA CCATGA GTG
TGG ATC CAG CTT GTC C and ATG CGG CCG CTC
ACA CGT CTT CAG GTT GCA TGT, subcloned into
pCR2.1 and verified to be free of mutations. After lineari-
zation with Xho I, the probe was labelled with digoxigenin
by transcription with SP6. After hybridization the embryos
were washed once in a solution containing 2 × SSC, pH 4.5,
50 % formamide and 0.1 % Tween 20 at 70 °C, then twice at
room temperature and finally three times at 65 °C. After
cooling to room temperature and three washes in TBST
(NaCl 8 g/l, KCl 0.2 g/l, 0.25 M Tris, pH 7.5, Tween-20
(1 %)), the embryos were incubated in blocking solution
(10 % heat-inactivated sheep serum) for 1 h and thereafter
incubated with anti-digoxigenin Fab alkaline phosphate con-
jugate (Roche, Stockholm, Sweden) in TBST with 1 % heat-
inactivated sheep serum. This step was followed by antibody
conjugate incubation overnight at 4 °C. The antibody conju-
gate was removed in a series of washes, first with TBST at
room temperature and then with APB. The embryos were
stained using Vectashield (Vectorlab Inc., Burlingame, USA)
and the embryos were thereafter rinsed in PBS containing 1M
EDTA (Sigma-Aldrich, Stockholm, Sweden). Morula- and
blastocyst-stage embryos incubated without the probe served
as negative controls. A total of 67 embryos were used in this
study.
In situ hybridization of NANOG in human embryonic stem
cells
Embryonic stem cells were fixed on dishes together with
feeder cells and processed in the same way as embryos.
Mouse ESCs and human skin fibroblasts served as negative
control cells.
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Immunostaining of NANOG and OCT4 in human
embryonic stem cells
Human embryonic stem cells were fixed with 4 % paraformal-
dehyde in PBS for 20 min at room temperature and thereafter
washed with PBS and blocked with 5 % goat serum in PBS.
Permeabilisation was carried out using blocking buffer consist-
ing of 0.02 % TritonX-100 in PBS. Primary antibodies—
monoclonal mouse antibodies for OCT4 (sc-5279, Santa Cruz
Biotechnologies, Santa Cruz, USA), diluted 1:80, and mono-
clonal goat antibody for NANOG (MAB1997, R&D systems,
Minneapolis, MN USA), diluted 1:200—were added in 5 %
blocking buffer overnight at 4 °C and washed three times with
PBS to remove any unbound primary antibodies. Secondary
antibodies—FITC-conjugated goat anti-mouse IgG and FITC-
conjugated bovine anti-goat IgG (both from Chemicon)—were
diluted 1:200 in 5 % blocking buffer and applied to the cells for
60 min at RT in the dark. For controls, the primary antibodies
were excluded from the staining protocol. Stained cells were
viewed with a Zeiss Axiovert 200 M inverted microscope
equipped with fluorescence optics and appropriate filters and
images were acquired using Openlab 3.1.3 software. Human
skin fibroblasts served as negative control cells.
Immunostaining of NANOG and OCT4 in human
preimplantation embryos
Human preimplantation embryos were rapidly transferred from
culture and briefly washed in PBS containing PVP (3 mg/ml)
and then fixed in 2.5 % paraformaldehyde in PBS for 15 min at
room temperature. Following fixation, the embryos were per-
meabilised in PBS/PVP buffer containing 0.25 % Triton X 100
for 30 min. The embryos were then placed in blocking buffer
containing 0.1 % BSA and 0.01 % Tween 20 in PBS for
15 min. Primary antibodies—monoclonal mouse antibody for
OCT4 (Santa Cruz Biotechnologies, Santa Cruz, USA), diluted
1:100, and monoclonal goat antibody for NANOG (R&D
systems, Minneapolis, MN USA), diluted 1:100—were added
in blocking buffer and incubated overnight at 4 °C. The em-
bryos were then washed 3 times for 15 min each in blocking
buffer to remove any unbound primary antibodies. The sec-
ondary antibodies—Alexa 568 conjugated rabbit anti-goat
(1:250) and Alexa 488 conjugated rabbit anti-mouse (1:100)
antibodies (Invitrogen, Stockholm, Sweden), respectively—
were diluted in blocking buffer and applied to the embryos
for 60 min at RT in the dark. For negative controls, the primary
antibodies were excluded from the staining protocol. After
incubation the embryos were briefly washed through a series
of 25, 50, 75 and 100 % citifluor (with DAPI) and then
mounted on slides in antifade medium under coverslips. The
coverslips were then sealed with nail varnish. Stained embryos
were viewed with an inverted microscope equipped with fluo-
rescence optics and appropriate filters.
Data from gene array studies
Data from gene array studies performed at Karolinska Institutet
[34] were used for comparison with data from the present
study.
Ethical considerations
The pre-implantation embryos used in this study were donated
with informed consent by couples undergoing in vitro fertil-
ization treatment. Only pre-implantation embryos that could
not be used in infertility treatment were used in the study. The
human embryonic stem cells were derived from the inner cell
masses of blastocysts that could not be used for infertility
treatment. Approval was obtained from the Research Ethics
Committee of Örebro University Hospital for expression stud-
ies in human pre-implantation embryos, and from the Ethics
Board of Karolinska Institutet for derivation of hES cell lines,
and studies regarding their properties. Both partners of the
couples involved signed an informed consent form after re-
ceiving oral and written information [1]. No reimbursement
was given to the couples.
Results
Presence of NANOG and OCT4 proteins in human
pre-implantation embryos
Using immunohistochemistry, we observed immunostaining
of NANOG and OCT4 in human pre-implantation embryos
(n031). This immunostaining was seen in an eccentrically
located group of cells in the morula and in part of the ICM
of blastocyst-stage embryos (Fig. 1a, b, c and d). Double
staining showed that OCT4 and NANOG were present in
the same cells of the ICM (Fig. 1d and e). There was also
some staining of OCT4 in trophoblast cells, but no such
staining as regards NANOG (Fig. 1d and e).
Expression of NANOG mRNA in human pre-implantation
embryos
Expression of NANOG mRNA in human pre-implantation
embryos was determined by using whole-mount in situ
hybridization (n089). NANOG mRNA was expressed in
some cells of the compacted morula, with eccentric locali-
zation, and in the ICM of blastocyst-stage embryos
(Fig. 2d–f). No expression was detected in 2-cell, 4-cell or
8-cell stages (Fig. 2a–c). In the blastocyst, NANOG mRNA
was confined to the ICM and absent in the trophectoderm
(Fig. 2f).
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NANOG and OCT4 in human embryonic stem cells
Immunostaining showed the presence of NANOG and OCT4
proteins in all embryonic stem cells, although the staining was
apparently weaker in the centre of the colony (Fig. 3b and g).
Nuclear Hoechst DNA staining also showed the presence of
feeder cells, which were negative for NANOG and OCT4
(Fig. 3c and g). NANOG mRNAwas evenly expressed in all
cells in the stem cell colonies. In situ hybridization showed
NANOGmRNA in a colony of HS235 hESCs on human skin
Fig. 1 Representative pictures
show double staining of OCT4
and NANOG in the human
morula and blastocyst. a
Immunostaining of OCT4 in the
morula. b Immunostaining of
NANOG in the same morula. c
DAPI staining in the morula. d
Staining of OCT4 in the
blastocyst. Immunostaining is
seen both in the inner cell mass
and the trophoblast; arrows. e
Staining of NANOG in the
same blastocyst. Staining is
seen only in the inner cell mass;
arrow. f DAPI staining in the
same blastocyst. g Exclusion of
OCT4 antibody. h Exclusion of
NANOG antibody. i DAPI
staining of the embryo without
primary antibodies present
Fig. 2 In situ hybridization of NANOG in the human pre-implantation embryo. a 2-cell embryo, day 1. b 4-cell embryo, day 2. c 8-cell embryo,
day 3. d morula, day 4. e late day 4 embryo. f blastocyst, day 5. g mouse ESCs hybridized with human NANOG primer
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fibroblast feeder cells (Fig. 3d and e). Mouse stem cells did
not show any staining after in situ hybridization with human
NANOG probe (Fig. 1f).
Gene array data
Data from gene array studies showed that NANOG mRNA is
present in pre-implantation embryos from day 2 and is highly
expressed in hESCs (Table 1). OCT4was weakly expressed in
pre-implantation embryos and highly expressed in stem cells
(Table 1). The two genes were absent in fibroblasts (Table 1).
Discussion
We localized the expression of NANOG and Oct4 in human
pre-implantation embryos and in three human embryonic
stem cell lines derived in our laboratory. The time of ap-
pearance (early morula), resembled that in mouse embryos
[3, 12, 24, 25]. We found that the expression of NANOG in
human compacted morula was not evenly distributed, but
was strictly localized in the cells which apparently form the
inner cell mass 1 day later. The expression of NANOG in
human embryos seemed to be polarized earlier than in
mouse embryos (see Fig. 2d and e and [3]).
The present study revealed NANOG and OCT4 protein
and NANOG mRNA in the morula and blastocyst stages of
human embryos. In mouse embryos, NANOG and OCT4
have also been seen in the morula to the hatched blastocyst
stage [3, 12, 24, 25].
In the present study, some OCT4 immunostaining was
also seen in the trophoblast cells of the blastocyst, although
to a lesser extent than in the ICM. This has also been seen in
bovine blastocysts [16, 32] and is in line with the results of a
previous study showing the expression of mRNA for OCT4
in human trophoblast cells [9].
Additionally, we showed the expression of NANOG in
human embryos during morula and blastocyst stages by using
a whole-mount in situ hybridization technique. This method
gave us the unique opportunity to visualize the expression of
NANOG in both time and space in single human embryos. The
protocol proved to be reliable and sensitive for visualization of
NANOG gene expression in human embryos. This novel
technique can be used to determine the precise expression
Fig. 3 Immunostaining of
OCT4 and NANOG in human
embryonic stem cells, and in
situ hybridization of NANOG
in embryonic stem cells. a Light
microscopy of human
embryonic stem cells. b
NANOG immunostaining in
embryonic stem cells. The
feeder cells do not show
staining for NANOG (red
arrow). c Nuclear staining of
embryonic stem cells and
fibroblast cells. DAPI staining
is seen in feeder cells (blue
arrow). d & e In situ
hybridization showing NANOG
mRNA in embryonic stem cells.
NANOG f Mouse embryonic
stem cells hybridized with
human NANOG primer. g
OCT4 immunostaining of stem
cell line HS426 (green). Blue
colour shows nuclear DAPI
staining
Table 1 Data from microarray
analysis of human embryos and
embryonic stem cells and fibro-
blasts. For Nanog, the average
signal intensity from one probe set
and for Oct4 the average number
of three probe sets is shown
Gene Signal intensity
Day 2 embryos Day 3 embryos Day 5 embryos Stem cells Fibroblasts
Nanog 98.6 194.6 196.8 391.8 1.3
Oct4 32.2 67.1 46.8 310.9 5.3
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pattern of a gene of interest at various stages of development.
Furthermore, it can be used to elucidate the genes and path-
ways involved in cellular processes such as differentiation,
proliferation and apoptosis.
Differently from mouse embryos, the expression of
NANOG was not centred at the middle of the morula. This
confirms that the early human embryo is polarized at early
stages, and our findings show clear polarization during the
morula stage. The concept of polarization of the early em-
bryo has been discussed in connection with the expression
of hCG in early embryos [10, 11]. The distribution of
mitochondria has been reported to be polarized in human
oocytes and early embryos [31].
Embryonic stem cells can be derived from and reintro-
duced to the ICM, but this does not necessarily mean that
these cells are exactly equivalent. The ICM exists only
transiently and does not operate as a stem cell compartment
in vivo. Stem cells might arise through selection and adap-
tation to the culture environment [2, 29]. Two transcription
factors, Oct4 and NANOG, appear to define the potency of
human and mouse ESCs. NANOG plays a fundamental role
in maintaining pluripotential properties of embryonic stem
cells. In a recent study [28], it was shown that ICM cells in
NANOG-null embryos failed to develop into viable epiblast.
NANOG Octamer and SOX elements, which control
NANOG transcription, are able to recruit OCT4 and
SOX2, respectively.
This results in upregulation of NANOG gene expression
[33]. In another study it was shown that OCT4, NANOG and
SOX2 were co-expressed in porcine epiblasts [5]. Human
embryonic stem cells were stained positive both for NANOG
and OCT4 [12]. Furthermore, Göke J et al. [7], observed that
the combinatorial binding of OCT4, NANOG and SOX2 is
critical for transcription in mouse and human ES. In the
present study, we showed immunostaining for both NANOG
and OCT4 using both immunohistochemistry and in situ
hybridisation.
Whole-mount in situ hybridization has, as far as we know,
not previously been used for detection of genes in human
embryos. This technique permits the direct observation of
the protein synthesis capacity of particular genes. Previously,
the most commonly used method has been paraffin embed-
ding and sectioning of embryos [23]. Whole-mount in situ
hybridization provides a sensitive and powerful method for
detection of expression patterns of genes within an individual
preimplantation embryo.
Gene array data showed the presence of NANOG mRNA
from D2 stage. This analysis was performed using an addi-
tional amplifying step before array analysis, showing that
this method is more sensitive in detection of a gene com-
pared with in situ hybridization. Recently it was shown that
NANOG and OCT4 cDNA are present in 4- and 8-cell
human embryos, expression being restricted to the ICM [6].
We showed that the expression profile of NANOG in
humans resembles that in mice, suggesting that NANOG
plays a physiological role in preimplantation development
of the human embryo and it also provides a useful molecular
marker of pluripotency. There is clear polarization of
NANOG-expressing cells in human compacted morula to
those cells which are probably defined to form the ICM.
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Leukaemia inhibitory factor receptor and gp130
in the human Fallopian tube and endometrium before
and after mifepristone treatment and in the human
preimplantation embryo
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Leukaemia inhibitory factor (LIF) is a cytokine, which is associated with reproductive processes such as embryo development and
implantation. The objectives of this study were to detect the presence of LIF receptor (LIFR) and glycoprotein 130 (gp 130) in the
human Fallopian tube, endometrium and preimplantation embryo and to study the effect of mifepristone on the expression of
LIFR and gp130 in the Fallopian tube. Twenty-two healthy fertile women received a single dose of 200 mg mifepristone or
placebo immediately after ovulation (LH12). Biopsies were obtained from the Fallopian tubes during laparoscopic sterilization
once between days LH14 and LH16 and from endometrium once between days LH16 and LH18. Preimplantation embryos
were received from couples undergoing in vitro fertilization treatment. Immunohistochemistry was used to detect the presence
of LIFR and gp130 in the Fallopian tube, endometrium and preimplantation embryo. Real-time PCR was used to study LIFR
and gp130 expression in the Fallopian tube and endometrium. LIFR and gp130 were localized in the Fallopian tube, preimplanta-
tion embryo and endometrium. LIFR was more abundant in the Fallopian tube than in the endometrium. In the blastocyst, the
staining of gp130 was mainly localized in the inner cell mass, whereas LIFR was expressed in all cells. The presence of LIFR and
gp130 in the Fallopian tube and preimplantation embryo indicates a role for LIF in communication between the embryo and the
Fallopian tube. Mifepristone did not affect the expression of LIFR and gp130 in the Fallopian tube, nor in the endometrium
suggesting that progesterone might not be directly involved in the regulation of LIFR or gp130.
Keywords: embryo/endometrium/Fallopian tube/gp130/LIF receptor
Introduction
Normal microenvironment and function of the Fallopian tube are of
vital importance for human reproduction. The densely ciliated fimbrial
apparatus of the Fallopian tube picks up the ovum directly after
ovulation. The ovum is thereafter transported into the ampulla,
where it is fertilized (Pauerstein and Eddy, 1979). Following this,
the embryo undergoes cleavage and development while being trans-
ported through the Fallopian tube, over a period of 3 days, after
which it reaches the uterine cavity where it will hatch and implant
(Croxatto et al., 1978).
Leukaemia Inhibitory Factor (LIF) is a cytokine, which regulates
differentiation, proliferation and survival of various cells in the in the
embryo as well as in the adult (Gearing, 1993), such as embryonic
stem cells (Smith et al., 1992), primordial germ cells (Matsui et al.,
1991) and peripheral neurons (Yamamori, 1992). LIF has been shown
to be involved in a number of processes in reproduction such as
enhancement of sperm motility and survival (Attar et al., 2003) and in
the physiology of ovulation (Arici et al., 1997). LIF enhances blastocyst
formation and hatching (Lavranos et al., 1995) and has been shown to be
essential for implantation in mouse (Stewart et al., 1992). LIF also
increases implantation rates in sheep (Fry et al., 1992). It is known
that addition of LIF to the culture medium significantly increases blasto-
cyst formation in human embryos (Dunglison et al., 1996).
The importance of LIF in human implantation is still uncertain.
Infertile women show dysfunction in LIF production and it has been
observed that infertile women have less LIF in uterine secretion
than women with proven fertility (Laird et al., 1997; Hambartsoumian,
1998; Lass et al., 2001). However, the LIF content in uterine secretion
at the time of oocyte retrieval does not seem to be correlated to preg-
nancy rate (Olivennes et al., 2003).
LIF exerts its biological effects by interaction through its specific
LIF receptor (LIFR). The LIFR forms a high affinity heterodimer
complex with glycoprotein 130 (gp130) (Robinson et al., 1994). The
gp130 trans-membrane subunit can also, as a monomer, act as
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interleukin-6 (IL-6), interleukin-11 (IL-11) and ciliary neutrophic
factor (CNTF) receptor (Auernhammer and Melmed, 2000).
Expression of mRNA activity for LIFR and gp130 has been
demonstrated in human preimplantation embryos (Sharkey et al.,
1995; Chen et al., 1999), but the localization of LIFR and gp130 in
human preimplantation embryos has to our knowledge not been
reported.
LIF is produced in the human Fallopian tube. The highest levels are
seen in the luminal epithelium of the ampulla, where the embryo first
develops before its transport into the uterine cavity for implantation
(Keltz et al., 1996; Li et al., 2004). Co-culture of mouse embryos
with human oviductal cells will result in maintained mitochondrial
function, decreased apoptosis in the embryo and a higher degree of
blastocyst formation and hatching (Xu et al., 2000, 2001, 2003). Cul-
tured bovine oviductal cells synthesize LIF that conditions the embryo
for implantation (Reinhart et al., 1998). LIFR and gp130 are also of
great importance at later stages of embryogenesis and fetal develop-
ment (Lavranos et al., 1995; Modric et al., 2000, Mitchell et al., 2002).
The expression of LIF and its receptor in human endometrium
increases around the time of implantation and was demonstrated to
appear simultaneously with pinopodes (Aghajanova et al., 2003).
LIF is believed to be a regulatory factor essential for implantation
of the blastocyst through autocrine and paracrine interaction
between LIF and its receptor in the luminal epithelium (Cullinan
et al., 1996; Cheng et al., 2002). Gp130 is most abundantly expressed
at the time of implantation (Classen-Linke et al., 2004), when
increased secretion of soluble gp130 was seen (Sherwin et al.,
2002). LIFR and gp130 mRNA is also expressed in the decidua and
may play a key role during the decidualization and placentation (Ni
et al., 2002). It has been shown that the secretion of gp130 was
reduced in infertile women (Sherwin et al., 2002).
Progesterone is essential for the development of endometrial recep-
tivity. Treatment with a progesterone receptor antagonist, such as
mifepristone, directly after ovulation reduces endometrial LIF
expression at the expected time of implantation (Cameron et al.,
1997; Danielsson et al., 1997). Mifepristone acts by competitive
binding to the progesterone receptor. (Rauch et al., 1985; Teutsch
et al., 1988). Treatment with mifepristone increases the expression
of progesterone receptors (Christow et al., 2002; Sun et al., 2003)
but has no effect on the expression LIF in the human Fallopian tube
(Li et al., 2004).
Taken together LIF is an important cytokine in the female reproduc-
tive tract and in the preimplantation embryo. Still data on LIF and LIF
receptor regulation is scarce and very little is known about possible
communication between the embryo and the Fallopian tube. There-
fore, the objective of the present study was to reveal the localization
of LIFR and gp130 in the human Fallopian tube and preimplantation
embryo and, in addition, to study the effect of mifepristone on these
receptors in the human Fallopian tube and endometrium.
Materials and methods
Study subjects
Twenty-two healthy women (age 31–44 years) were included in the study. All
women had proven fertility and had regular menstrual cycles (range 25–35
days). None of the women had taken any hormonal treatment or used an
IUD for at least 3 months prior the study.
Collection of Fallopian tube tissue
Sixteen women were randomly allocated to receive treatment with a single dose
of 200 mg mifepristone (n ¼ 8) immediately after ovulation (LHþ2) or to a
control group (n ¼ 8). Randomization was performed using opaque, numbered
and sealed, envelopes. Laparoscopic sterilization was performed by placement
of a silicone rubber ring over a segment of the isthmic part of the Fallopian tube
(Yoon and King, 1975). The surgery was performed on day LHþ4 to LHþ6,
which corresponds to the time of development and transport of the preembryo
within the Fallopian tube. At surgery, biopsies were obtained from both Fallo-
pian tubes. On one side biopsies were obtained from the isthmic part and on the
other side from the ampullary part. The biopsies were immediately snap-frozen
and stored in liquid nitrogen until analysed.
Collection of endometrial tissue
Endometrial biopsies were obtained from six healthy women during a control
cycle on day LHþ6 to LHþ8, which corresponds to the assumed time of
embryo implantation (Martel and Psychoyos, 1981; Nikas et al., 1995). An
additional biopsy was obtained from the same women in the following cycle,
after treatment with a single dose of 200 mg mifepristone immediately after
ovulation (LHþ2). The biopsies were obtained by curettage of the uterus
using a Randall curette without prior dilatation of the cervix. Samples for
immunohistochemistry were fixed in 4% formaldehyde for a maximum of
24 h and then stored in 70% ethanol until embedding. Samples for real-time
PCR were snap-frozen and stored in liquid nitrogen until analysed.
Collection of human preimplantation embryos
Eighty human preimplantation embryos were received from patients under-
going in vitro fertilization (IVF) treatment. The preimplantation embryos
were in all different stages from 2 cell embryos to hatching blastocysts.
Ethics
The study was approved by the local ethics committee at the Karolinska
University Hospital/Karolinska Institutet. All women gave their written
informed consent before entering the study. The embryos used in this study
were donated by couples undergoing IVF treatment. Only embryos that
could not be used for infertility treatment were used in the present study.
Both partners in the couple signed an informed consent form after receiving
oral and written information. No reimbursements were given to the couples.
Menstrual cycle monitoring
The day of the LH surge was estimated using a self-test detecting urinary LH
(Clearplan, Searle Unipath, Bedford, UK) twice daily from cycle day 10 to the
LH peak. In addition, all women collected daily urine during the cycle for
analysis of estrone- and pregnanediol-glucuronide and LH using radioimmuno-
assay (Cekan et al., 1986).
Immunohistochemistry of Fallopian tube and endometrium
Biopsies from the Fallopian tube were mounted in an embedding medium
(OTC Compound; Miles Inc., Elkhart, IN, USA) and serially sectioned to
9 mm using a Reichert-Jung Cryocut 1800 (Cambridge Instruments GmbH,
Nussloch). The sections were mounted on glass slides and immersed in 2%
paraformaldehyde in phosphate-buffered saline (PBS). The mounted sections
were then wrapped in parafilm and stored in 2708C until use.
Paraffin embedded biopsies from the endometrium was sectioned to 4 mm
and mounted on glass slides. The samples were thereafter deparaffinated in Bio-
clear (CiAB, Stockholm, Sweden) and rehydrated in decreasing concentrations
of ethanol ending up in PBS.
All samples from the Fallopian tube and endometrium were hereafter treated
in the same way. The samples were rinsed in PBS, incubated in darkness for
30 min in H2O2 (0.3 % in methanol) to block endogenous peroxidase activity
and washed with PBS/BSA (Albumin, Bovine 0.05%). Hereafter the slides
were blocked with 10% horse serum (in PBS/BSA) for 30 min. The sections
were then incubated with the primary antibody, diluted 1:50 for LIFR and
1:25 for gp130, over night at 48C. The primary antibody for LIFR was an
affinity-purified goat polyclonal antibody (AF-249-NA, R&D Systems Inc.),
raised against human LIFR. The antibody for gp130 was a goat polyclonal anti-
body (AF-228-NA, R&D Systems Inc.), raised against gp130 of human origin.
For negative control, the primary antibody was replaced with non-immune
serum of equivalent concentration from the same species. The slides were
washed in PBS/BSA and thereafter incubated with the secondary antibody
diluted 1:300 (horse anti-goat) for 30 min at room temperature. The slides
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were then rinsed in PBS/BSA, prior to incubation with ABC complex (Vectas-
tain Elite ABC immunoperoxidase detection system, Vector Laboratories Inc.,
Burlingame, CA, USA) according to the manufacturer’s instructions. After
washing with PBS/BSA, freshly prepared diaminobenzidine-hydrogen per-
oxide solution (DAB kit from Vector) was added to the slides, which were
thereafter rinsed with distilled water. The slides were counterstained with
10% Mayer’s Haematoxylin (VWR, Stockholm, Sweden), then washed in
cold water and mounted with glycerol-gelatine.
Two persons evaluated the immunohistochemical staining independently,
blinded to the identity of the samples. When the evaluation of the slides
turned out differently, the average value was used. The staining was graded
on a scale of 0 ¼ no staining of cells, þ¼faint staining, þþ ¼ moderate stain-
ing and þþþ ¼ strong staining.
Immunohistochemistry of embryos
The embryos were rapidly transferred from culture and briefly washed in PBS
containing 3 mg/ml polyvinylpyrrolidone (PVP) and then fixed with 2.5% par-
aformaldehyde in PBS for 15 min at room temperature. Following fixation, the
embryos were permeabilized in PBS/PVP buffer containing 0.25% Triton X
100 for 30 min. Thereafter the embryos were placed in PBS blocking buffer
containing 0.1% BSA and 0.01% Tween 20 for 15 min. The same primary anti-
bodies as used for the endometrium and Fallopian tube were added in blocking
buffer. For negative control, the primary antibody was replaced with non-
immune serum of equivalent concentration from the same species. The
embryos were incubated overnight at 48C. The embryos were then washed
three times for 15 min each in blocking buffer to remove any unbound
primary antibodies. The secondary antibodies, Alexa 568 conjugated rabbit
anti-goat (1:250), were diluted in blocking buffer and applied to the embryos
for 60 min at RT in the dark. After incubation, the embryos were briefly
washed through a series of 25, 50, 75 and 100% citifluor (with DAPI) and
then mounted on slides in antifade medium under a cover slip. Stained
embryos were viewed in an inverted microscope (Zeiss Axiovert 200M,
Germany) equipped with fluorescence optics and appropriate filters.
RNA and cDNA preparation
Total RNA was isolated using SV Total RNA Isolation System (Promega
Corp., Madison, WI, USA) according to the manufacturer’s protocol. One
microgram of each of the total RNA from each sample was reverse transcribed
using deoxynucleotide triphosphates (10 mM each), random hexamer (250 ng/
ml), ribonuclease inhibitor (40 U/ml) and Superscript reverse transcriptase
(200 U/ml), using the SuperscriptTM II RNase H2 Reverse Transcriptase Kit
(Invitrogen, Stockholm, Sweden).
Real-time PCR
Taqman real-time PCR (Applied Biosystems, Foster City, California, USA)
was used to quantify the differential expression of LIFR and GP130 in the Fal-
lopian tube (n ¼ 9) and endometrium (n ¼ 4).
Experiments were performed on a 96 well array format using the ABI
PRISM 7300 instrument (Applied Biosystems) incorporating the target assay
genes for LIFR or gp130 along with eukaryotic 18S rRNA as an internal
control, which was used to normalize the expression levels of target genes in
each sample. cDNA form human brain (Ambion, Austin, TX, USA) was
used as positive control for the expression of both LIFR and GP130. Fluoro-
genic probes were 50 labelled with 6-carboxyfluorescein (FAM) and 30 labelled
with MGB non-fluorescent quencher. Fluorescent signal detection used ‘ROX’
as the internal passive reference dye. The inoculum (25 ml) consists of 12.5 ml
Taqman universal PCR master mix (Applied Biosystems), 1.25 ml assay probe
(LIFR: Assay ID Hs00158730_m1, assay location bas 137 in the reference
sequence NM_002310.3, exons 1–2. The length of the product is 63. GP130:
Assay ID Hs00174360_m1, assay localization base 2016 in the reference
sequence NM_175767.1, exons 13–14 and assay location base 2099 exons
14–15. The length of the product is 72, Applied Biosystems), 6.25 ml
RNase/DNase free sterile water and 5 ml of diluted (1:2.5) cDNA. A standard
curve was performed for both GP130 and LIFR using serial dilution of cDNA
synthesized from endometrium, Fallopian tube and brain. After identifying the
appropriate dilution for the respective samples, the assay was performed as
follows: initial denaturation was carried out for 10 min at 958C, followed by
40 cycles of denaturation at 958C for 15 s and combined primer annealing/
extension at 608C for 1 min. All reactions were performed in triplicate and
the mean value of the threshold cycle (Ct, the start of exponential amplification)
of each sample was normalized with their respective threshold cycle of 18S,
obtaining the DCt value. Data was analysed using SDS 1.2.3 software
(Applied Biosystems). Relative expression was calculated using the following
formula 100  22DDCT as is described in User Bulletin number 2 from Applied
Biosystems.
Statistics
Nonparametric statistical evaluation, ANOVA on ranks, was performed for
differences in staining intensity for LIFR and gp130. Mann–Whitney Rank
Sum Test was performed to compare the mRNA levels. A P-value of ,0.05
was considered statistically significant.
Results
LIFR in the Fallopian tube
The most intense immunostaining was seen in the apical and basolat-
eral side of the luminal epithelial cells (Fig. 1A), in vessels (Fig. 1B)
and in the serosal epithelium of the Fallopian tube (Fig. 1C). There
was no difference in staining intensity between the isthmic and the
ampullary part of the Fallopian tube. Treatment with mifepristone
did not affect the staining intensity in any compartment of the Fallo-
pian tube (Figs. 1E–1G and 2A).
Gp130 in the Fallopian tube
Faint immunostaining for gp130 was seen in the luminal epithelium of
the Fallopian tube predominately in the isthmic part (Fig. 1I). Similar
immunostaining was also seen in the muscular wall, in some vessels
(Fig. 1J) and in the serosal surface epithelium (Fig. 1K). Treatment
with mifepristone did not affect the staining intensity in any compart-
ment of the Fallopian tube (Figs. 1M–O and 2B).
LIFR in the endometrium
Moderate immunostaining for LIFR was seen in the luminal and
glandular epithelium of the endometrium (Fig. 1Q and R). Some
faint staining was also seen in the endometrial stroma and in some
vessels (Fig. 1Q and S). There was no change in staining intensity
after mifepristone treatment (Fig. 1S and T).
Gp130 in the endometrium
Moderate immunostaining for gp130 was seen in the luminal and
glandular epithelium of the endometrium (Fig. 1V and W). There
was no change in staining intensity after mifepristone treatment
(Fig. 1X and Y).
Comparison of LIFR in Fallopian tube and endometrium
Taqman real-time PCR confirmed the presence of LIFR mRNA in the
Fallopian tube (Fig. 3A). The relative mRNA expression of LIFR in
the Fallopian tube was significantly higher than that of the endome-
trium, P ¼ 0.006 (Fig. 3A).
Comparison of gp130 in the Fallopian tube and endometrium
Real-time PCR confirmed the presence of gp130 mRNA in the Fallo-
pian tube (Fig. 3B). There was no significant difference in the relative
expression between the mRNA levels of gp130 in the Fallopian tube
compared with the endometrium, P ¼ 0.792 (Fig. 3B).
LIFR and gp130 in Fallopian tube, endometrium and embryo
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Figure 1: Representative pictures of immunostaining for LIFR and gp130 in the Fallopian tube (A–P) and endometrium (Q–Z) with and without mifepristone
treatment are shown. (Arrows indicating staining in: LE, luminal epithelium; V, vessels; S, serosal epithelium; GE, glandular epithelium). (A) LIFR in luminal
epithelium without treatment. (B) LIFR in muscular layer without treatment. (C) LIFR in serosal epithelium without treatment. (D) Negative control. (E) LIFR
in luminal epithelium after mifepristone treatment. (F) LIFR in muscular layer after mifepristone treatment. (G) LIFR in serosal epithelium after mifepristone treat-
ment. (H) Negative control. (I) gp130 in luminal epithelium without treatment. (J) gp130 in muscular layer without treatment. (K) gp130 in serosal epithelium
without treatment. (L) Negative control. (M) gp130 in luminal epithelium after mifepristone treatment. (N) gp130 muscular layer after mifepristone treatment.
(O) gp130 in serosal epithelium after mifepristone treatment. (P) Negative control. (Q) LIFR in luminal epithelium without treatment. (R) LIFR in glandular epi-
thelium without treatment. (S) LIFR in luminal epithelium after mifepristone treatment. (T) LIFR in glandular epithelium after mifepristone treatment. (U) Negative
control. (V) gp130 in luminal epithelium without treatment. (W) gp130 in glandular epithelium without treatment. (X) gp130 in luminal epithelium after mifepris-
tone treatment. (Y) gp130 in glandular epithelium after mifepristone treatment. (Z) Negative control.
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LIFR in human preimplantation embryos
Fluorescence microscopy showed presence of LIFR in all preembryo-
nic stages and in all cell types from the 2 cell stage to the expanded
blastocysts (Fig. 4A–F).
Gp130 in human preimplantation embryos
Fluorescence microscopy showed staining of gp130 in the embryonic
cells. Embryos up to the morula stage showed staining in all cells
(Fig. 4H–K). In early blastocysts and in a hatching blastocyst, the
gp130 staining was located to the inner cell mass (Fig. 4L and M).
Discussion
It is known that LIF is present in the human embryo (Chen et al., 1999;
Sharkey et al., 1995) endometrium and Fallopian tube (Senturk and
Arici, 1998). The present study shows the presence of LIFR and
gp130 in the luminal epithelium of the Fallopian tube and in preim-
plantation embryos, suggesting paracrine interactions involving LIF
between the developing embryo and the Fallopian tube in addition
to autocrine interactions occurring within the developing embryo
and the Fallopian tube.
Under the influence of progesterone there is a ‘cross-talk’ or
exchange of signals between the developing embryo and the maternal
tract to ensure synchronization between the blastocyst and the recep-
tive endometrium and thus render implantation possible
(Hombach-Klonisch et al., 2005). Progesterone is a key hormone in
human embryo implantation (De Ziegler et al., 1994; Jabbour et al.,
2006). In the endometrium, the highest levels of LIF and LIFR are
seen during the midsecretory phase, when serum progesterone levels
are high (Charnock-Jones et al., 1994; Kojima et al., 1994; Arici
et al., 1995; Aghajanova et al., 2003).
Mifepristone is a potent antiprogestin that blocks the action of pro-
gesterone at the receptor level (Klein-Hitpass et al., 1991; Gemzell-
Danielsson et al., 1993). Treatment with mifepristone has earlier
been shown to increase the progesterone receptor level in the Fallo-
pian tube (Sun et al., 2003). Administration of 200 mg mifepristone
on day LH þ2 has been shown to be a highly effective contraceptive
method (Gemzell-Danielsson et al., 1993) probably acting mainly by
adversely affecting endometrial receptivity (Gemzell-Danielsson and
Hamberg, 1994). Although this regimen had no effect on LIF
expression in the Fallopian tube on day LH þ4 to þ6, the same treat-
ment resulted in significantly reduced expression of LIF in endo-
metrial glandular epithelium on day LH þ6 to þ8 (Li et al., 2004).
A daily low dose contraceptive regimen of mifepristone had similar
Figure 2: Staining intensity of LIFR and gp130 in the Fallopian tube. (A) Immunostaining of LIFR in the luminal epithelium of the Fallopian tube with and without
mifepristone treatment. (B) Immunostaining of gp130 in the luminal epithelium of the Fallopian tube with and without mifepristone treatment.
Figure 3: (A) Relative expression of LIFR mRNA in Fallopian tube compared with the relative expression of LIFR mRNA in the endometrium normalized to 18S
rRNA expression (P ¼ 0.006). (B) Relative expression of gp130 mRNA in Fallopian tube compared with the the relative expression of gp130 mRNA in the endo-
metrium normalized to 18S rRNA expression (ns).
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effect on endometrial LIF expression at the expected time of receptiv-
ity (Cameron et al., 1997). The importance of LIF in endometrial
receptivity and implantation is further supported by studies of cyto-
kines in hydrosalpingeal fluid that show the presence of LIF in 50%
of patients with hydrosalpinges (Strandell et al., 2004). Removal of
hydrosalpinges in infertile patients resulted in increased endometrial
LIF expression at the time of implantation (Seli et al., 2005) and
improved results after IVF treatment (Strandell et al., 2001). Further-
more, in infertile women uterine flushings at the time of implantation
demonstrated significantly lower amounts of LIF compared with
fertile women (Laird et al., 1997). It has also been shown that the
secretion of gp130 was lower in infertile women compared with
fertile women (Sherwin et al., 2002).
In the present study, higher levels of LIFR mRNAwere found in the
Fallopian tube compared with the endometrium. The human embryo is
known to produce LIF (Chen et al., 1999). The presence of LIFR in the
Fallopian tube emphasise the importance of LIF for the tubal microen-
vironment. The present study shows that gp130 is located to the inner
cell mass in the hatching blastocyst, whereas LIFR did not seem to be
localized to a specific cell type. Therefore, is could be suggested that
the targets of LIF produced by the blastocyst is the cells in the inner
cell mass or the endometrium rather than autocrine/paracrine inter-
actions with the cells in the trophoblast. The mechanism in the Fallo-
pian tube might be different, where LIF produced by the embryo acts
both within the embryo and with the Fallopian tube in an auto- and
paracrine manner. This might explain why there are higher levels of
LIFR in the Fallopian tube than in the endometrium. In contrast,
gp130 expression showed no difference between The Fallopian tube
and endometrium. This may be due to the fact that gp130 alone
binds other cytokines such as IL6, which is known to be produced
by the human embryo (Austgulen et al., 1995).
LIFR and gp130 did not change after mifepristone treatment. This
indicates that progesterone is not the main regulator of LIFR and
gp130 in the Fallopian tube and endometrium. In immortalized endo-
metrial epithelial cells, LIF, LIFR and gp130 were unaffected after
oestrogen and/or progesterone treatment (Hombach-Klonisch et al.,
2005). This was also seen in the western spotted skunk, where prolac-
tin, rather than progesterone, had an effect on the LIFR expression
(Passavant et al., 2000). However, in endometrial epithelial and in
endometrial decidual cells, a significant increase in secretion of
soluble gp130 was observed after estradiol/progesterone treatment
(Classen-Linke et al., 2004).
In conclusion, we found expression of LIFR and gp130 in the
human Fallopian tube where it may facilitate the paracrine interaction
with the embryo during its transport into the uterus. Furthermore, the
staining pattern of LIFR and gp130 in the human preimplantation
embryo suggests an embryonic regulation of the communication
through LIFR and gp130. The communication through LIFR
between the preembryo and the Fallopian tube might be important
for the embryo development, and /or establishment of pregnancy. In
addition, we conclude that progesterone is not likely to be a direct reg-
ulator of these receptors.
Acknowledgements
Authors thank the research nurses Lena Ellfors-So¨derlund and Margareta
Hellborg and the staff at the gynaecological wards at the Karolinska University
Hospital, Stockholm, Sweden, for excellent care of the volunteers and patients.
Also special thanks to Associate Prof. Sten Cekan and Anna Hildenbrand for
valuable assistance with the manuscript. The study was supported by grants
from the Center for Health Care Sciences, the Swedish Research Council
(2003-6392, 2005-7293), ALF, The Swedish Society of Medicine, Karolinska
Institutet and the A˚ke Wibergs Foundation.
References
Aghajanova L, Stavreus-Evers A, Nikas Y et al. Coexpression of pinopodes
and leukemia inhibitory factor, as well as its receptor, in human
endometrium. Fertil Steril 2003;79(Suppl 1), 808–814.
Arici A, Engin O, Attar E et al.Modulation of leukemia inhibitory factor gene
expression and protein biosynthesis in human endometrium. J Clin
Endocrinol Metab 1995;80:1908–1915.
Arici A, Oral E, Bahtiyar O et al. Leukaemia inhibitory factor expression in
human follicular fluid and ovarian cells. Hum Reprod 1997;12:1233–1239.
Attar E, Ozsait B, Bulgurcuoglu S et al. Effect of leukaemia inhibitory factor
on long-term sperm motility and survival. Reprod Biomed Online
2003;7:71–74.
Auernhammer CJ, Melmed S. Leukemia-inhibitory factor-neuroimmune
modulator of endocrine function. Endocr Rev 2000;21:313–345.
Austgulen R, Arntzen KJ, Vatten LJ et al. Detection of cytokines
(interleukin-1, interleukin-6, transforming growth factor-beta) and soluble
tumour necrosis factor receptors in embryo culture fluids during in-vitro
fertilization. Hum Reprod 1995;10:171–176.
Cameron ST, Critchley HO, Buckley CH et al. Effect of two antiprogestins
(mifepristone and onapristone) on endometrial factors of potential
importance for implantation. Fertil Steril 1997;67:1046–1053.
Cekan SZ, Beksac MS, Wang E et al. The prediction and/or detection of
ovulation by means of urinary steroid assays. Contraception 1986;33:
327–345.
Charnock-Jones DS, Sharkey AM, Fenwick P et al. Leukaemia inhibitory
factor mRNA concentration peaks in human endometrium at the time of
implantation and the blastocyst contains mRNA for the receptor at this
time. J Reprod Fertil 1994;101:421–426.
Figure 4: Immunostaining of LIFR and gp130 in human preimplantation embryos. Staining for LIFR: (A) 2 cell embryo (B) 4-cell embryo. (C) 8-cell embryo
(D) Morula. (E) Early blastocyst. (F) Expanded blastocyst. (G) Negative control). Staining for gp130: (H) 2-cell embryo (I) 4-cell embryo. (J) 8-cell embryo
(K) Morula. (L) Early blastocyst. (M) Staining of the inner cell mass in a hatching blastocyst. (N) Negative control.
Wa˚nggren et al.
396
 at :: on A
pril 15, 2014
http://m
olehr.oxfordjournals.org/
D
ow
nloaded from
 
Chen HF, Shew JY, Ho HN et al. Expression of leukemia inhibitory factor and
its receptor in preimplantation embryos. Fertil Steril 1999;72:713–719.
Cheng JG, Rodriguez CI, Stewart CL. Control of uterine receptivity and
embryo implantation by steroid hormone regulation of LIF production and
LIF receptor activity: towards a molecular understanding of “the window
of implantation”. Rev Endocr Metab Disord 2002;3:119–126.
Christow A, Sun X, Gemzell-Danielsson K. Effect of mifepristone and
levonorgestrel on expression of steroid receptors in the human Fallopian
tube. Mol Hum Reprod 2002;8:333–340.
Classen-Linke I, Muller-Newen G, Heinrich PC et al. The cytokine receptor
gp130 and its soluble form are under hormonal control in human
endometrium and decidua. Mol Hum Reprod 2004;10:495–504.
Croxatto HB, Ortiz ME, Diaz S et al. Studies on the duration of egg transport by
the human oviduct. II. Ovum location at various intervals following
luteinizing hormone peak. Am J Obstet Gynecol 1978;132:629–634.
Cullinan EB, Abbondanzo SJ, Anderson PS et al. Leukemia inhibitory factor
(LIF) and LIF receptor expression in human endometrium suggests a
potential autocrine/paracrine function in regulating embryo implantation.
Proc Natl Acad Sci USA 1996;93:3115–3120.
Danielsson KG, Swahn ML, Bygdeman M. The effect of various doses of
mifepristone on endometrial leukaemia inhibitory factor expression in the
midluteal phase—an immunohistochemical study. Hum Reprod
1997;12:1293–1297.
De Ziegler D, Fanchin R, Massonneau M et al. Hormonal control of
endometrial receptivity. The egg donation model and controlled ovarian
hyperstimulation. Ann NY Acad Sci 1994;734:209–220.
Dunglison GF, Barlow DH, Sargent IL. Leukaemia inhibitory factor
significantly enhances the blastocyst formation rates of human embryos
cultured in serum-free medium. Hum Reprod 1996;11:191–196.
Fry RC, Batt PA, Fairclough RJ et al. Human leukemia inhibitory factor
improves the viability of cultured ovine embryos. Biol Reprod
1992;46:470–474.
Gearing DP. The leukemia inhibitory factor and its receptor. Adv Immunol
1993;53:31–58.
Gemzell-Danielsson K, Hamberg M. The effect of antiprogestin (RU 486) and
prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid
prostaglandin F2 alpha concentrations. Hum Reprod 1994;9:1626–1630.
Gemzell-Danielsson K, Swahn ML, Svalander P et al. Early luteal phase
treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod
1993;8:870–873.
Hambartsoumian E. Endometrial leukemia inhibitory factor (LIF) as a possible
cause of unexplained infertility and multiple failures of implantation. Am J
Reprod Immunol 1998;39:137–143.
Hombach-Klonisch S, Kehlen A, Fowler PA et al. Regulation of functional
steroid receptors and ligand-induced responses in telomerase-immortalized
human endometrial epithelial cells. J Mol Endocrinol 2005;34:517–534.
Jabbour HN, Kelly RW, Fraser HM et al. Endocrine regulation of menstruation.
Endocr Rev 2006;27:17–46.
Keltz MD, Attar E, Buradagunta S. et al. Modulation of leukemia inhibitory
factor gene expression and protein biosynthesis in the human fallopian
tube. Am J Obstet Gynecol 1996;175:1611–1619.
Klein-Hitpass L, Cato AC, Henderson D et al. Two types of antiprogestins
identified by their differential action in transcriptionally active extracts
from T47D cells. Nucl Acids Res 1991;19:1227–1234.
Kojima K, Kanzaki H, Iwai M et al. Expression of leukemia inhibitory factor in
human endometrium and placenta. Biol Reprod 1994;50:882–887.
Laird SM, Tuckerman EM, Dalton CF et al. The production of leukaemia
inhibitory factor by human endometrium: presence in uterine flushings and
production by cells in culture. Hum Reprod 1997;12:569–574.
Lass A, Weiser W, Munafo A et al. Leukemia inhibitory factor in human
reproduction. Fertil Steril 2001;76:1091–1096.
Lavranos TC, Rathjen PD, Seamark RF. Trophic effects of myeloid leukaemia
inhibitory factor (LIF) on mouse embryos. J Reprod Fertil 1995;105:
331–338.
Li HZ, Sun X, Stavreus-Evers A et al. Effect of mifepristone on the expression
of cytokines in the human Fallopian tube. Mol Hum Reprod
2004;10:489–493.
Martel D, Psychoyos A. Estrogen receptors in the nidatory sites of the rat
endometrium. Science 1981;211:1454–1455.
Matsui Y, Toksoz D, Nishikawa S et al. Effect of Steel factor and leukaemia
inhibitory factor on murine primordial germ cells in culture. Nature
1991;353:750–752.
Mitchell MH, Swanson RJ, Oehninger S. In vivo effect of leukemia inhibitory
factor (LIF) and an anti-LIF polyclonal antibody on murine embryo and fetal
development following exposure at the time of transcervical blastocyst
transfer. Biol Reprod 2002;67:460–464.
Modric T, Kowalski AA, Green ML et al. Pregnancy-dependent expression of
leukaemia inhibitory factor (LIF), LIF receptor-beta and interleukin-6 (IL-6)
messenger ribonucleic acids in the porcine female reproductive tract.
Placenta 2000;21:345–353.
Ni H, Ding NZ, Harper MJ et al. Expression of leukemia inhibitory factor
receptor and gp130 in mouse uterus during early pregnancy. Mol Reprod
Dev 2002;63:143–150.
Nikas G, Drakakis P, Loutradis D et al. Uterine pinopodes as markers of the
‘nidation window’ in cycling women receiving exogenous oestradiol and
progesterone. Hum Reprod 1995;10:1208–1213.
Olivennes F, Ledee-Bataille N, Samama M et al. Assessment of leukemia
inhibitory factor levels by uterine flushing at the time of egg retrieval does
not adversely affect pregnancy rates with in vitro fertilization. Fertil Steril
2003;79:900–904.
Passavant C, Zhao X, Das SK et al. Changes in uterine expression of
leukemia inhibitory factor receptor gene during pregnancy and its
up-regulation by prolactin in the western spotted skunk. Biol Reprod
2000;63:301–307.
Pauerstein CJ, Eddy CA. The role of the oviduct in reproduction; our
knowledge and our ignorance. J Reprod Fertil 1979;55:223–229.
Rauch M, Loosfelt H, Philibert D et al. Mechanism of action of an
antiprogesterone, RU486, in the rabbit endometrium. Effects of RU486 on
the progesterone receptor and on the expression of the uteroglobin gene.
Eur J Biochem 1985;148:213–218.
Reinhart KC, Dubey RK, Mummery CL et al. Synthesis and regulation of
leukaemia inhibitory factor in cultured bovine oviduct cells by hormones.
Mol Hum Reprod 1998;4:301–308.
Robinson RC, Grey LM, Staunton D et al. The crystal structure and biological
function of leukemia inhibitory factor: implications for receptor binding.
Cell 1994;77:1101–1116.
Seli E, Kayisli UA, Cakmak H et al. Removal of hydrosalpinges increases
endometrial leukaemia inhibitory factor (LIF) expression at the time of the
implantation window. Hum Reprod 2005;20:3012–3017.
Senturk LM, Arici A. Leukemia inhibitory factor in human reproduction. Am J
Reprod Immunol 1998;39:144–151.
Sharkey AM, Dellow K, BlayneyM et al. Stage-specific expression of cytokine
and receptor messenger ribonucleic acids in human preimplantation
embryos. Biol Reprod 1995;53:974–981.
Sherwin JR, Smith SK, Wilson A et al. Soluble gp130 is up-regulated in the
implantation window and shows altered secretion in patients with primary
unexplained infertility. J Clin Endocrinol Metab 2002;87:3953–3960.
Smith AG, Nichols J, Robertson M et al. Differentiation inhibiting activity
(DIA/LIF) and mouse development. Dev Biol 1992;151:339–351.
Stewart CL, Kaspar P, Brunet LJ et al. Blastocyst implantation depends on
maternal expression of leukaemia inhibitory factor. Nature 1992;359:76–79.
Strandell A, Lindhard A,Waldenstrom U et al.Hydrosalpinx and IVF outcome:
cumulative results after salpingectomy in a randomized controlled trial.Hum
Reprod 2001;16:2403–2410.
Strandell A, Thorburn J, Wallin A. The presence of cytokines and growth
factors in hydrosalpingeal fluid. J Assist Reprod Genet 2004;21:241–247.
Sun X, Christow A, Marions L et al. Progesterone receptor isoform B in the
human fallopian tube and endometrium following mifepristone.
Contraception 2003;67:319–326.
Teutsch G, Ojasoo T, Raynaud JP. 11 beta-substituted steroids, an original
pathway to antihormones. J Steroid Biochem 1988;31:549–565.
Xu J, Cheung TM, Chan ST et al. Human oviductal cells reduce the incidence
of apoptosis in cocultured mouse embryos. Fertil Steril 2000;74:1215–1219.
Xu JS, Chan ST, Ho PC et al. Coculture of human oviductal cells maintains
mitochondrial function and decreases caspase activity of cleavage-stage
mouse embryos. Fertil Steril 2003;80:178–183.
Xu JS, Cheung TM, Chan ST et al. Temporal effect of human oviductal cell and
its derived embryotrophic factors on mouse embryo development. Biol
Reprod 2001;65:1481–1488.
Yamamori T. Molecular mechanisms for generation of neural diversity and
specificity: roles of polypeptide factors in development of postmitotic
neurons. Neurosci Res 1992;12:545–582.
Yoon IB, King TM. A preliminary and intermediate report on a new
laparoscopic tubal ring procedure. J Reprod Med 1975;15:54–56.
LIFR and gp130 in Fallopian tube, endometrium and embryo
397
 at :: on A
pril 15, 2014
http://m
olehr.oxfordjournals.org/
D
ow
nloaded from
 



